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ABSTRACT
Malaria is a parasitic disease that is caused by the plasmodium parasite. Plasmodium infection has
affected man for thousands of years. With advances in drug discovery over the past century, malaria has
evolved to possess resistance to most mainline therapeutics. This war of drug discovery vs plasmodium
evolution continues to be fought to this very day, with attempts to eradicate malaria worldwide. Frontline
treatments such as chloroquine, artemisinin, and atovaquone/proguanil have all seen parasitic resistance
in strains of P. vivax as well as P. falciparum. While plasmodium possesses resistance to most classes of
anti-malarials, the 8-aminoquinoline (8-AQ) class has seen minimal resistance development. 8-AQs have
been shown to be effective against erythrocytic and exo-erythrocytic forms of plasmodium, and are often
given in combination with a blood schizonticide such as chloroquine or artemisinin. These combinations
clear all forms of plasmodium infection. With 8-AQs unique set of anti-malarial properties and the advent
of increased drug resistance to other drugs, much research is being done to understand 8-AQs mechanism
of action and toxicity. 8-AQ use is limited due to inducing extreme hemolytic anemia in those with
glucose-6-phosphate dehydrogenase (G6PD) deficiency. Primaquine is the only 8-AQ molecule available
on the market with tafenoquine, an analog primaquine, currently in phase III clinical trials. It is believed
that if the mechanism of action and toxicity of the 8-AQs are understood, then we can create new
generation anti-malarials that will maintain the unique action of 8-AQs while reducing their toxicity.
Studies have shown that 8-AQ mechanism of action has been attributed to the generation of unstable
metabolites that induce ROS production in the parasite, as well as mitochondrial swelling. While there is
some evidence suggesting molecular targets of 8-AQs, the actual target is still unknown. When 8-AQs is
given in combination with chloroquine, a synergistic effect is observed. While chloroquine has no activity
against liver stages, it still somehow potentiates primaquine’s activity in those stages. This mechanism of
synergy in liver stages is not well understood, and its understanding can give us increased understanding
of basic plasmodium biology in the liver. Additionally, more information about the mechanisms of action
vi

of both chloroquine and primaquine could be elucidated. Tagging drugs with fluorescent probes is a
technique that can give much information about the drug’s pharmacological activity in vitro, and
sometimes in vivo as well. Such an approach has been used for various disease states such as HIV and
cancer. Malaria is no exception; fluorescent probes of artemisinin and chloroquine have been used to
examine resistance mechanisms to both molecules. In addition to 8-AQs, there are other older antimalarials that have received attention recently due to increases in resistance. Menoctone, a
hydroxynapthoquinone that subsequently lead to the discovery of atovaquone, has recently gained
increased attention because of its similarities to atovaquone. Research surrounding menoctone was
abandoned due to the discovery of more efficacious compounds. Similar to 8-AQs, understanding the
mechanisms of action and resistance to menoctone could give us much more information about
plasmodium responses to this class of compounds. This understanding could potentially lead to the
discovery of novel therapeutics. To understand mechanisms of action and synergy of 8-AQs, we report
the creation of novel fluorescent probes of the 8-AQ molecules primaquine and tafenoquine. The organic
synthesis was designed and characterization was confirmed by NMR and high resolution mass spectra,
and the fluorescent properties were examined using absorbance and steady-state emission experiments.
We found that the anti-malarial, anti-leishmaniasis, and cytotoxic properties of these novel probes were
similar to the parent compounds. These probes localized in the cytoplasm of infected parasites in vitro.
We also attempted to view their localization in liver stage infection, and investigated the synergistic
combination of 8-AQs with chloroquine and quinine. Menoctone resistance was induced in vivo to
determine mechanisms of resistance. Cross resistance to atovaquone was observed, and the mutation
responsible for resistance was also found.
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CHAPTER 1: INTRODUCTION
MALARIA HISTORY
Malaria, the disease caused by the Plasmodium parasite, originally got its name from medieval Italian,
meaning “bad air” (mal-bad, aria-air) (1). When malaria was first described, it was believed to be an
airborne disease. It wasn’t until 2000 years later that it was discovered that malaria was transmitted by the
anopheles mosquito via a very delicate and complicated system of infection. Over the next several
millennia, Plasmodium infection would continue to ravage communities all over the world. In China, the
Artemisia annua plant was used to treat fever and was one of the first antimalarial treatments to be used
before the parasite would be identified. In the late 19th century quinine would be discovered as a
treatment, and Plasmodium parasites would first be observed by geimsa stain. There are several species
that infect man, each with varying severity. Plasmodium falciparum, vivax, malaria, ovale, and knowlsei
infect humans, with falciparum and vivax being the most deadly. Plasmodium has evolved to hundreds of
different species that infect birds, pigs, primates, rodents, and other mammalian species. The definitive
host is the anopheles mosquito, while the intermediate hosts are often mammalian vertebrates.
LIFE CYCLE
The life cycle of Plasmodium begins when an infected mosquito takes a blood meal from an animal. The
infected mosquito injects sporozoites from its salivary glands, which migrate to the liver within 30
minutes. Once in the liver, the sporozoites infect hepatic cells. Sporozoites tend to pass through several
hepatic cells killing them in the process. They select for certain hepatocytes, but how this selection occurs
is unknown. Once the appropriate hepatocyte is selected, the sporozoites begin asexual reproduction,
forming hepatic schizont forms filled with merozoites. These merozoite forms, which are responsible for
blood stage infection, rupture from the hepatic schizonts, circulate via the blood stream, and begin
1

infecting erythrocytes. In vivax and ovale infections, it is believed that dormant forms of the parasite
known as hypnozoites form a reservoir in hepatic cells and are responsible for relapsing infection. This
theory however, remains a source of debate (2).
The invasion of erythrocytes by merozoites is mediated by several signaling processes and events.
Merozoites invaginate into the erythrocyte to begin infection. Merozoites then turn into the first asexual
form known as rings, or young trophozoite forms. These forms are described as rings due to their
structure resembling a jewelry ring, characterized by a round cytoplasmic form, and the nucleus
resembling the ‘jewel’. Depending on the species of infection, these forms last between 22-24 hours. The
next form is the mature trophozoite stage, characterized by the food vacuole (responsible for heme
digestion), nucleus, and active heme metabolism and digestion. It is active for 6-8 hours. The final form is
the schizont form, where multiple merozoites have been created, each with its own nucleus. The schizont
subsequently ruptures the erythrocyte, where the merozoites are released and are free to infect other
erythrocytes to continue the cycle. In P. falciparum, vivax, and ovale the cycle takes 48 hours. For
malariae however, the cycle can take up to 72 hours(3).
It is believed that the ring stage form of Plasmodium differentiates into the male and female sexual forms
of malaria known as gametocytes. Gametocyte growth, known as gametogenesis, occurs in five stages
each with their own characteristic structure and molecular functions. The later stages of gametocytes (IVV) are responsible for transmission to the anopheles mosquito. This is known as the sexual stage of
replication; stage V gametocytes differentiate into male and female forms. When an uninfected mosquito
takes a blood meal from an infected person, the mosquito ingests the mature gametocytes. The
gametocytes then turn into gametes which mate inside the mosquito, then forms a zygote, which
progresses to an ookinete form. This ookinete then forms an oocyst in the midgut of the mosquito. The
oocyst then develops over 10-14 days until mature sporozoites form. Once the oocyst ruptures, the
sporozoites migrate from the midgut to the salivary glands, where they are injected into an uninfected
2

person during a blood meal, beginning the cycle all over again. Figure 1.1 shows a graphical
representation of the life cycle.

Figure 1.1- Life cycle of the malaria parasite. Open source document from the NIAID, 2012
PATHOLOGY
Severity of infection differs greatly between parasite strains. Falciparum malaria is much more deadly
than vivax malaria due to falciparum causing severe and cerebral malaria symptoms that often lead to
death. Vivax infection is usually described as benign tertian malaria, and doesn’t cause severe disease
unless other factors are present that exacerbate the infection such as malnutrition, co-infections, or mixed
malaria infection (4).
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Typically, malaria infection is seen as uncomplicated or severe, and treatment options differ depending on
the type. The symptoms of malaria are primarily due to asexual replication within erythrocytes, as well as
morphological changes and protein expression that occur within these stages. Each replication cycle over
a period of 48 hours produces symptoms that are congruent with the various asexual stages. The set of
symptoms usually associated with uncomplicated malaria infection include fever, chills, headache,
nausea, fatigue, and vomiting. Physical presentations may include sweating, enlarged spleen and liver,
and increased breathing rate. In severe malaria, symptom presentation may include coma, severe anemia,
acute kidney failure, metabolic acidosis, bacterial meningitis and convulsions. These symptoms are often
the result of extremely high parasite burdens, metabolic disorders or organ failure when infected with
Plasmodium (5). Parasite rupture of erythrocytes as well as complement mediated lysis is associated with
fever/chills, increased inflammation and anemia. Sequestration of infected erythrocytes results in reduced
blood flow throughout the body and is thought to be an essential event leading to cerebral malaria.
Sequestration of parasites is exacerbated by cytoadherence of infected erythrocytes. The expression of the
PfEMP1 protein on the surface of infected erythrocytes adheres to the endothelial lining of capillaries,
resulting in a ‘rolling’ phenomenon that inhibits proper circulation of infected and non-infected
erythrocytes alike. Symptom presentation of severe/cerebral malaria can differ between adults, children,
and pregnant women (4).
Children can sometimes carry parasite burdens while being asymptomatic, though in endemic areas,
severe disease can occur quickly. One life threatening symptom is usually present as opposed to many
symptoms in non-immune adults. When children present multiple life threatening symptoms, the
prognosis is usually much worse, often leading to death. While cerebral malaria is more deadly than
malarial induced anemia, anemia results in more deaths due to its increased prevalence. Severe malarial
anemia causes more healthy erythrocytes to be ruptured as the disease progresses.
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In non-immune adults, severe malaria can be common when they are infected with P.falciparum. Clinical
manifestations of severe falciparum malaria in adults differ from the pediatric version of the disease, and
include cerebral malaria, jaundice, pulmonary edema, and kidney failure. Additionally, travelers from
non-endemic regions are much more susceptible than those who reside in endemic regions who may have
acquired partial immunity over time.
Women in endemic areas acquire some immunity to malaria after years of exposure. However, once
becoming pregnant, their susceptibility increases. This greatly affects the newborn with low birth weight,
and significantly contributes to infant mortality in malaria endemic regions. Severe malaria is also more
likely to occur, with parasites sequestering around the placenta. This sequestration affects the
development of the fetus, leading to birth complications, developmental defects in the newborn and even
maternal mortality (4).
IMMUNIZATION AND HUMAN HOST PROTECTION MECHANISMS
Immunity and Immunization
Natural and/or acquired immunity to malaria can affect a number of factors in Plasmodium infection.
From initial transmission to the production of gametocytes to chemotherapeutic outcomes, the effects of
immunity on Plasmodium biology is vast.
In areas endemic with malaria, immunity increases with age, which explains why most malaria related
deaths are due to severe malaria in children under the age of 5. After this age malaria related deaths
sharply decline, but susceptibility to non-life threatening episodes continues. Evidence for this age related
trend was observed in a study of naive adults traveling to malaria endemic regions; the adults acquired
immunity more rapidly than children from the area (6). Further evidence for this phenomenon was
observed when children and adults were treated with chloroquine against parasites that were chloroquine
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resistant. As the age of the afflicted increased, their ability to clear parasites after treatment with
chloroquine also increased (7).
Immune responses could target any stage to which humans are exposed. Immune responses to exoerythrocytic and sexual stages have been observed, but the effects on transmission are unclear.
Furthermore, there is evidence that naturally acquired immunity is predominantly against erythrocytic
stages and is antibody mediated. Antibodies may act by clearing infected erythrocytes or by acting against
merozoites before erythrocytic infection (8, 9). Antibody and spleen clearance of infected erythrocytes
results in the lysis of erythrocytes, leading to the characteristic anemia symptom of malaria pathology.
The relative importance of each antibody clearance mechanism is still a source of debate. The most likely
scenario is that the various mechanisms act in concert to offer protection against Plasmodium infection.
One of the main goals for malaria eradication is the production of a safe vaccine with long term protection
and efficacy. This vaccine would need to have the ability to focus on eliminating the parasitic infection
prior to clinical manifestations associated with blood stage infection. It is believed that the portion of the
life cycle most vulnerable to vaccine protection is the point of mosquito to host transmission, or transfer
from the definitive (Anopheles) host to the intermediate host. Despite millions of sporozoites being
injected upon mosquito bite, very few make it to the liver to begin infection. No host immune protection
is ever elicited against these forms despite repeated infection (10). The majority of research efforts have
surrounded either the RTS,S/AS01 vaccine or the PfSPZ vaccine. RTS,S/AS01 is currently considered the
gold standard to which all future vaccines will be compared, due to it being the most successful vaccine
candidate until very recently. The RTS,S/AS01 is an anti-sporozoite vaccine which is currently in phase
III clinical trials. RTS,S/AS01 is comprised of a liposome-based adjuvant (AS01) and a hepatitis B virus
surface antigen (HBsAg) virus-like particles which incorporates a portion of the P. falciparum derived
circumsporozoite protein (CSP) fused to HBsAg (11). CSP is a protein that covers the surface of
Plasmodium spp. sporozoites. RTS,S/AS01 confers protection against malaria parasites, but this
6

protection has a short duration and is mildly successful in reducing parasite burdens in children and
infants (8, 12).
The second vaccine candidate is the PfSPZ vaccine, which is a radiation-attenuated, whole-cell sporozoite
vaccine. This vaccine has recently entered phase III clinical trials as well, and was found to achieve >80%
sterile protection against controlled human malaria infection (CHMI) with homologous falciparum
parasites. Further studies showed that the PfSPZ vaccine also confers protection against heterologous
CHMI for up to 33 weeks after the final immunization, and that protection against heterologous vs
homologous CHMI is a dose dependent phenomenon (13). Both vaccines offer great promise, but both
have been limited in that they’ve only been screened against CHMI rather than heterogeneous natural
exposure. Age specific immunization, screening in pregnant women and immunocompromised subjects
and responses in malaria endemic populations must all be addressed before these vaccine candidates can
be used in widespread eradication efforts (14).
Human Host Protection Mechanisms
Glucose 6 Phosphate Dehydrogenase Deficiency. Glucose-6-Phosphate Dehydrogenase (G6PD)
Deficiency is an X-linked genetic disorder that results in mutations in the G6PD gene. G6PD is an
enzyme that is present in the pentose phosphate pathway, which is responsible for supplying energy in the
form of ATP to cells and also maintaining levels of nicotinamide adenine dinucleotide phosphate
(NADP+). NADP+ then maintains levels of glutathione which protect the cell from oxidative damage
from ROS. G6PD catalyzes the rate limiting step of the pentose phosphate pathway, which is the
reduction of NADP+ to NADPH:
D-glucose 6-phosphate + NADP+

6-phospho-D-glucono-1,5-lactone + NADPH + H+

Due to G6PD’s importance in the pentose phosphate pathway, its inhibition or lack of function would
have significant downstream effects. G6PD deficiency affects millions worldwide, and is associated with
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many clinical presentations. Neonatal jaundice, cardiovascular disease, and hemolytic anemia are
common clinical presentations of the deficiency. 8-aminoquinolines, a class of anti-malarial drugs, are
known for causing severe hemolytic anemia in those with G6PD deficiency. However, G6PD deficiency
has been positively correlated with increased resistance to malaria infection, as well as areas that are
endemic with malaria. One study in African children with G6PD deficiency displayed a 46-58% reduction
in severe malaria risk among them (15). Other studies suggest that parasite loads are lower in cells with
deficient enzyme activity rather than normal levels (16). Taken together, these studies show that parasite
proliferation is impaired in individuals with G6PD deficiency. How G6PD deficiency confers antimalarial resistance is currently unknown. It is hypothesized that red cells in G6PD deficient individuals
may be under increased oxidative stress, which is a toxic environment for P. falciparum parasites.
Additionally, those G6PD deficient cells that are infected by ring stage parasites have impaired antioxidant defenses and maybe more likely to undergo phagocytosis, leading to reduced numbers of mature
parasites (16).
Thalassemia. Thalassemia is a genetic blood disorder that results in abnormal hemoglobin
formation. It is an autosomal recessive trait that affects individuals in the Middle East, parts of Europe,
northern Africa and Asia. This abnormal hemoglobin formation is due to the type of thalassemia present,
and there are two types of thalassemia; alpha and beta. In normal adult hemoglobin, there are four protein
chains (2 alpha and 2 beta) arranged in a heterotetramer structure. Alpha thalassemia affects the
duplicated alpha-chain genes and causes underproduction of alpha-globin chains. Beta-thalassemia affects
the single beta chain and causes abrogation or underproduction of beta chains (16). Both versions of
thalassemia confer partial protection against malaria infection. In -thalassemia, erythrocytes infected
with Plasmodium parasites bind high levels of antibodies from malaria endemic sera. This causes a
downstream effect which ultimately results in the clearance of infected erythrocytes by immunity
mechanisms such as compliment mediated lysis, opsonization, and inhibition of sequestration of infected
erythrocytes. In -thalassemia, protection is conferred by reduced rates of severe malaria infection, or by
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increasing phagocytosis of infected erythrocytes (17). Whether or not the individual is homozygous or
heterozygous for either  or  thalassemia also seems to affect the degree of protection, but the extent and
significance of this protection is still a matter of debate (16, 17).
Sickle Cell Anemia. Sickle-cell disease (SCD) is a group of autosomal recessive genetic blood
disorders. It is one of the most prevalent erythrocytic alterations in malaria endemic regions. The most
common presentation is known as sickle-cell anemia. It results in a mutation in the hemoglobin B (HBB)
gene which changes the form of the hemoglobin S. Homozygous SCD is often fatal in early life without
proper treatment. Even with proper treatment, homozygous SCD individuals still experience a shorter life
span (16). Malaria attacks and deaths are increased in homozygous SCD individuals, and it is suggested
that they consider life-long malaria chemoprophylaxis in endemic areas. This however, comes with its
own risks, as life-long chemotherapy could increase side effects, impair natural immunity tolerance to
malaria, and increase parasitic resistance to the drugs (18). Those who are heterozygous for SCD have
less clinical crises and milder symptoms. Additionally, they enjoy a degree of protection from
Plasmodium infection. Studies have shown that these heterozygous individuals are protected against
severe malaria episodes, and even have lower parasitemia burdens in uncomplicated malaria infection
(16, 17). Two main theories surround the mechanisms of protection conferred by heterozygous mutation.
The first is that intra-erythrocytic parasite growth is inhibited by hemoglobin S polymerization when
oxygen levels drop below 5%. The second is that parasite-infected sickle erythrocyte phagocytosis by
host immune cells is done at a much higher rate compared to infected normal erythrocytes. It has also
been shown that hemoglobin S erythrocytes infected by P. falciparum lower the expression of PfEMP-1,
which results in a reduction of cytoadherence and subsequent protection from severe malaria (17, 19).
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MALARIA CHEMOTHERAPEUTICS: MECHANISMS OF ACTION AND RESISTANCE
Arylamino Alcohols
Quinine (QN). Quinine is an aromatic alkaloid that was discovered in the mid-1800s. It was
initially isolated from the bark of the Peruvian Cinchona tree and became one of the first mainstay
treatments as an anti-malarial (20). It is fast acting with a short half-life, and has been recommended for
the treatment of uncomplicated malaria in pregnant women and even for drug resistant parasites (21, 22).
Despite its efficacy as an anti-malarial, its use alone is limited due to long treatment regimens as well as
side effects such as blurred vision, tinnitus, headache and nausea. Therefore, QN is often given in
combination with other anti-malarials such as doxycycline, or in artemisinin combination therapy (ACT),
which enhances its anti-malarial activity and efficacy. It even has fluorescent activity, and is sometimes
used for fluorescence studies in photochemistry (23). QN anti-malarial mechanism of action has been
investigated by various studies. One study links its mechanism to the digestive vacuole via fluorescence
localization, showing that it localizes to a non-acidic compartment within the digestive vacuole (24).
Other structural studies have shown that it forms complexes with ferriprotoporphin IX (FP). These
complexes are -oxo dimers which are stabilized by  stacking interactions. These interactions are
important for the stability of the complex and QN anti-malarial activity, as this complex is toxic to the
parasite. These complexes have been studied in detail, as they occur with other anti-malarials containing
the quinoline pharmacophore such as chloroquine and quinidine (25, 26). QN resistance in isolates is rare,
most likely due to QN short half-life in vivo. In vitro studies suggest that decreased susceptibility to QN is
due to mutations in the PfNHE-1 gene, which codes for a Na+/H+ exchanger. There is a microsatellite
polymorphism consisting of DNNND repeat units, which has been defined as ms4760. Variant ms4760
with two copies of DNNND repeat units was associated with reduced QN sensitivity in vitro (27, 28).
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However, this evidence was found to possibly be dependent on the genetic background of the parasites
and/or geographic origin (28).
Mefloquine (Mfq). Mefloquine is a synthetic anti-malarial that was synthesized as an analog of
quinine. Mfq has found much success as an anti-malarial, and is effective against all species of
Plasmodium that infect humans. Additionally, it is one of the few anti-malarials that is effective against
all the asexual forms of infection (25). It is therapeutically dosed once per week, allowing for good
compliance among users. It is often prescribed to travelers going to malaria endemic regions as a
prophylactic. Its pharmacokinetics is characterized by low oral clearance, a large apparent volume of
distribution and a long half-life, though individual differences have been observed (29). Mfq mechanism
of action is a matter of debate. As an analog of QN, it possesses a shared mechanism according to various
studies. These studies indicate that Mfq, like QN, inhibits the ingestion of host cell hemoglobin by
potentially interfering with the endocytic process. Another study found that Mfq could treat drug resistant
cancer cells in vitro by inhibiting p-glycoprotein (30). This specific inhibition has been implicated as a
mechanism for anti-malarial activity; the homolog PfPgh1 is expressed as an integral digestive vacuole
membrane protein. This is critical, since QN and Mfq share similar mechanisms via action in the digestive
vacuole, inhibition of this protein could be a significant contributor to Mfq mechanism of action (25).
Further evidence of PfPgh1 contribution to Mfq mechanism of action is also implicated in parasites
resistant to Mfq and QN. Plasmodium resistance to Mfq has been found to be linked to PfMDR1 as well
as Pgh1 expression. Clinical isolates that are resistant to Mfq display an increased copy number of the
PfMDR1 gene (31), as well as increased expression of Pgh1 (25).
Antifolates and Atovaquone
Sulfadoxine and Pyrimethamine (SP). The treatment combination of sulfadoxine and
pyrimethamine is known as fansidar, and is used to treat Plasmodium infection. Pyrimethamine was
found to have anti-malarial activity in the early 1950s, and was used for prophylaxis and as a
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monotherapy against P. falciparum infection. Sulfadoxine was found to be a slow acting blood
schizonticide in clinical trials almost a decade later. Shortly after sulfadoxine’s anti-malarial activity was
found, more studies revealed that faster action against malaria was found when the two drugs were
combined (32, 33). SP is often used as a first line anti-malarial treatment for several reasons. It is a
cheaper alternative to chloroquine, can be used to treat chloroquine resistant parasites, and it is safe for
use in pregnant women, children and even infants (33). The mechanism of action differs slightly for each
drug, yet they both act as anti-folate drugs due to their ability to competitively inhibit folate biosynthesis
required for pyrimidine biosynthesis in Plasmodium. Sulfadoxine inhibits dihydropteroate synthase
(DHPS), while pyrimethamine inhibits dihydrofolate reductase (DHFR). Both enzymes are essential for
parasite folate pathways, and thus, pyrimidine biosynthesis. This combination was found to be synergistic
in vitro against P. falciparum, and was used as an anti-malarial treatment and prophylaxis for pregnant
women and children (33). Unfortunately, resistance to SP quickly emerged after its use. The mechanism
of resistance to SP has been correlated with various mutations in the DHPS and DHFR genes. These
mutations subsequently result in clinical treatment failure. Additionally, it is worth noting that folic acid
supplements at standard therapeutic doses can reduce the antimalarial efficacy of these drugs (34), and
should be avoided if SP is to be prescribed for antimalarial treatment.
Proguanil. Proguanil is a synthetic anti-malarial prophylactic agent discovered in 1945. It is a
biguanide compound, a class which was found to have anti-malarial activity due to metabolism by
cytochrome enzymes. It gained popularity as a first line anti-malarial treatment when used with
Atovaquone. This Atovaquone/Proguanil combination (Malarone) treatment was found to have a
synergistic effect against Plasmodium parasites. It is well tolerated, administered orally, and can even be
used safely against uncomplicated malaria in pregnant women (25, 35). Proguanil’s mechanism of action
has been characterized by a number of studies. The consensus indicates that proguanil’s activity is due to
metabolism by CYP2C19 to the active metabolite Cycloguanil. Cycloguanil then acts as a potent inhibitor
of P.falciparum Dihydrofolate Reductase (PfDHFR) (36-38). Resistance in Plasmodium against
12

proguanil/cycloguanil is primarily caused by mutations in the PfDHFR gene. Proguanil is thought to have
a different target than cycloguanil, which may explain why malarone is such an effective treatment for
both sensitive and resistant parasites (37).
Atovaquone (ATQ). Atovaquone is a synthetic 2-hydroxynapthoquinone that was made in the
1980s. Investigations into using hydroxynapthoquinones as potential anti-malarials began during World
War II, a time when quinine supplies were incredibly short. ATQ is effective against diseases such as
Pneumocystis carinii pneumonia; when used in combination with other drugs such as proguanil or
azithromycin, it becomes a powerful treatment against malaria or babesiosis respectively. ATQ synthesis
results in a racemic mixture, with the trans isomer being more active than the cis isomer. Optimized
synthesis of ATQ was just recently described. This synthesis effectively separates the active trans isomer,
is higher yielding than previous synthetic routes, and doesn’t involve the use of heavy metals (39, 40).
ATQ/proguanil is prescribed as malarone, a frontline anti-malarial treatment used for uncomplicated and
drug resistant Plasmodium infection as well as prophylaxis. Malarone is well tolerated, administered
orally, and has few detrimental side effects. Due to ATQ being highly protein bound and more lipophilic,
it has an unusually long half-life (50-84 hours) when compared to other anti-malarials, and it is
recommended that ATQ be taken with a meal that is high in fat in order to increase ATQ bioavailability.
It is not extensively metabolized, nor is metabolism required for elimination, which primarily occurs in
the liver (41). ATQ mechanism of action has been extensively characterized and debated. It has been
found that ATQ is a competitive inhibitor of ubiquinol; specifically inhibiting the Plasmodium
mitochondrial electron transport chain by binding the cytochrome bc1 complex at or around the ubiquinol
oxidation (QO) site. This binding results in a collapse of the mitochondrial membrane potential (41-43).
ATQ is also capable of inhibiting dihydroorotate dehydrogenase (DHOD), which is required by
Plasmodium for pyrimidine biosynthesis. Therefore, the mechanism of action of ATQ can be attributed to
the combination of DNA synthesis inhibition as well as mitochondrial membrane collapse. When used in
combination with proguanil as malarone, parasite clearance is rapid and effective. It is even capable of
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acting against hepatic schizonts, though it isn’t capable of clearing hypnozoite forms. Using ATQ to clear
hepatic schizonts has been exploited to develop in vitro culturing methods to investigate hypnozoite
biology and detection (44). ATQ resistance in Plasmodium has been associated with a missense mutation
at position 268 in cytochrome b. These mutations exchange tyrosine for serine (Y268S) or sometimes
even asparagine (Y268N) or cysteine (Y268C). These mutations result in 1000-fold increased IC50 values
in vitro for ATQ and have been associated with Malarone drug failure, but these mutations come at a
fitness cost to the parasite (41, 45, 46).
Antibiotics
Clindamycin. Clindamycin is a licosamide antibiotic that also possesses anti-malarial properties.
It can be used as a monotherapy against P. falciparum infection, and is used to treat severe malaria. It has
minimal side effects, is orally efficacious, and is often given with quinine as a combination therapy.
However, it is slow acting and can take up to a week to clear parasites. Additionally, it isn’t capable of
acting against exo-erythrocytic forms responsible for relapsing infection in vivax malaria (21). Its
mechanism of action in bacteria targets protein synthesis by inhibiting the peptidyl transferase reaction on
the 50S ribosomal subunit (47). It affects malaria parasites by acting against the circular apicoplast
genome which harbors bacterial ancestry and biochemical function. Clindamycin combination with
quinine is often used to treat chloroquine resistant and sensitive strains of malaria infection due to its oral
efficacy as well as effective clearance of parasites. Clindamycin resistance in Plasmodium is still being
investigated, but studies have shown that resistance is conferred by a point mutation in the apicoplast
genome encoding 23S rRNA, which leads to a greater than 100 fold increase in the EC50 values for
clindamycin (48).
Doxycycline. Doxycycline is another antibiotic that is also effective against Plasmodium
infection. Like clindamycin, it is often given in combination with quinine. It is rapidly absorbed orally,
but activity can be varied due to the age of the patient and any other treatments provided along with it
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(49). It can be used as chemoprophylaxis for falciparum malaria, but there is evidence showing that
prophylaxis fails at times due to inadequate dosing and poor compliance (50). Nevertheless, when the
regimen is adequately followed, prophylactic failure rarely occurs. Its mechanism of action in
Plasmodium has not been well characterized, but studies suggest that it may directly inhibit mitochondrial
protein synthesis and decrease the activity of dihydroorotate dehydrogenase (DHOD) involved in de novo
pyrimidine synthesis. Further research suggests it may inhibit nucleotide and deoxynucleotide synthesis in
P. falciparum, but the concentrations needed for said inhibition are much higher than those given
therapeutically (50, 51). Characterizing resistance to doxycycline in Plasmodium parasites is not as
straightforward as with other anti-malarials. Doxycycline is given in combination with quinine, and
treatment failures with this combination are rare. Due to this phenomenon, quantifying resistance in
Plasmodium proves difficult. In order to attempt to elucidate a mechanism of resistance, studies have
been done to characterize bacterial resistance, and then attempt to correlate bacterial genetic changes to
their P. falciparum genetic homologs. While most theories point to plasmodial apicoplast genes playing a
role in resistance, there is little evidence for any definitive target or mechanism for doxycycline resistance
in Plasmodium (50).
4-aminoquinolines
Chloroquine (CQ). Chloroquine (originally called Resochin) was synthesized in the 1930s by
Hans Andersag. It was made as an analog of methylene blue in order to treat vivax malaria (52). Since its
discovery, CQ has been used as a frontline anti-malarial treatment all over the world. CQ has many
advantages to its use, including low toxicity, effective potency, and a long half-life. It is distributed
throughout the body, is 60% bound to plasma proteins, and is primarily cleared by the kidney and liver. It
is primarily metabolized by P450 enzymes (CYP2D6 and 3A) to its active forms desethylchloroquine and
bisdesethylchloroquine (53). While it was initially used as a treatment against malaria, it is also employed
as an adjuvant in cancer therapy.
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Many studies have been done to elucidate CQ’s mechanism of action and resistance. CQ mechanism of
action has been attributed to the inhibition of hemazoin biocrystallization. In Plasmodium parasites,
hemoglobin metabolism occurs in the acidic digestive vacuole of the parasite. After hemoglobin
metabolism, the parasite forms free heme which is crystallized to hemazoin. CQ inhibits this heme
crystallization process by binding to free heme, forming CQ-heme complexes. These complexes prevent
the formation of hemazoin, and are responsible for permeabilizing parasite cell membranes, leading to
parasite death (54, 55). This theory has been supported by localization studies using fluorescent analogs
of CQ to determine localization (56), cell fractionation studies using transmission electron microscopy
(55), and other studies quantifying amounts of free heme and hemazoin upon CQ treatment (7, 25, 57).
How CQ accumulates within the DV is a matter of some debate. Several theories attempt to explain this
phenomenon. In the weak base model, unprotonated CQ is the only form permeable in the membrane that
can diffuse into the erythrocyte up to the digestive vacuole. These forms become protonated then trapped,
as protonated forms cannot cross the membrane. The next theory is the carrier mediated mechanism, in
which a Na/H exchanger on the parasite plasma membrane is involved in CQ uptake with sodium ions.
The last theory is the “ferriprotoporphin IX receptor” model, in which free heme acts as a receptor for
CQ, and CQ entry into the digestive vacuole is regulated by the amount of free heme (58). In cancer, it
has various modes of action, including inhibition of multidrug resistance pumps and autophagy
(chemotherapy resistance mechanisms). While these effects were observed at higher doses, clinically
acceptable doses of CQ were found to increase the survival prospects of certain cancers when coadministered with chemo and radiation therapy (59).
Since the mechanism of action involves a host-derived target, resistance to CQ took over 20 years to
develop within Plasmodium parasites (52). The mechanism of resistance to CQ has also been extensively
studied, due to CQs widespread use and efficacy against malaria. Resistance to CQ by parasites is
characterized by decreased uptake of CQ in the parasite digestive vacuole. Several genes have been
implicated in this decreased uptake. One of them is the PfCRT gene (Plasmodium falciparum chloroquine
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resistance transporter). This gene codes the PfCRT protein which is localized in the parasite’s digestive
vacuole. In CQ resistant parasites, a consistent mutation is found at position 76 in the first transmembrane
domain. This K76T mutation has been found in multiple studies describing CQ resistance (25, 54, 58).
Another gene is the PfMdr1 (Plasmodium falciparum multidrug resistant transporter 1), which is has been
implicated in resistance to piperaquine as well as mefloquine. Studies have shown that partial CQ
resistance is conferred by mutations in the PfMdr gene, but the mutations alone are not enough to give
complete protection. It has been suggested that the increased frequency of pfmdr1 polymorphisms in
resistant parasites could be due to physiological compensation for the altered function of mutated pfcrt
(58).
Amodiaquine (AQ). Amodiaquine is a 4-aminoquinoline that is similar to CQ. It is often used to
treat uncomplicated falciparum malaria, and is a cheaper alternative to CQ, making it more widely used
and available. It is taken orally and is given to children for treatment due to it being more palatable than
CQ (60). AQ has mild and severe side effects, which has limited its use over time. The WHO even went
so far as to withdraw its use when travelers had fatal side effects when it was used as prophylaxis. While
it is no longer used as a first line treatment, it is still used to combat Plasmodium infection, as the WHO
determined it should be used if the risk of infection outweighs adverse drug reactions (60). Its mechanism
of action is similar to that of CQ as well. It is metabolized to its active metabolite, accumulates in the
digestive vacuole of the parasite and inhibits heme polymerization to hemazoin by complexing with
heme, preventing its degradation by glutathione (61). This causes a toxic buildup of heme inside the
parasite, leading to parasite death. AQ resistance has been attributed to mutations in the Pfcrt gene (62)
and Pfmdr1, which pumps the metabolite out of the digestive vacuole of the parasite before it can inhibit
heme polymerization in vitro and in vivo (62, 63).
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Piperaquine (PQP). Piperaquine is a bis-4-aminoquinoline that was synthesized in 1960. It is
structurally similar to chloroquine, one of the frontline treatments for malaria. PQP enjoys good in vitro
activity against chloroquine sensitive and resistant parasites. When it was first discovered, it was used for
prophylaxis, as well as a monotherapy to treat chloroquine resistant parasites (64). PQP is very slowly
absorbed, and subsequently has a long elimination half-life of approximately 22 days (65). Its use as a
monotherapy quickly resulted in the emergence of PQP resistant parasites, which resulted in limited use
by the 1980s. Now, PQP is primarily administered with dihydroartemisinin (DHA) as a part of
Artemisinin combination therapy (ACT). DHA is fast acting, and being paired with PQP allows their
differences in action to synergize their effects against Plasmodium parasites (65). PQP mechanism of
action has not been thoroughly investigated, but it is thought that it is similar to chloroquine in that it
binds heme in the digestive vacuole and prevents its detoxification by the parasite. This idea becomes
even more interesting when PQP resistance is studied. Despite having a similar mechanism of action to
chloroquine, PQP treatment it not hindered by CQ resistance mechanisms. This would imply that the
parasite develops two distinct mechanisms of resistance to PQP and CQ, despite them having similar
modes of action (64, 65). It has also been found that in P. berghei, PQP resistance is stable over multiple
passages, but comes at a fitness cost to the parasite (66).
Endoperoxides
Artemisinin and other artemisinin relatives such as artelinic acid (AA), dihydroartemisinin (DHA),
artesunate, and arteether are endoperoxide-containing compounds. Artemisinin was discovered as a
natural product of the Artemisia annua plant, called “Qinghao” by the Chinese. This discovery was made
in 1972 by Youyou Tu, a researcher working with the Chinese military force. The Artemisia plant has
been used to treat fever, jaundice and toxic blood conditions. The extracts from Artemisia annua were
found to clear rodent malaria parasites with a clearance rate of 95-100%. With anti-malarial resistance on
the rise and no vaccination prospects in sight, novel therapeutics were desperately needed (1).
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Artemisinin and its derivatives have been used successfully to treat acute P. falciparum malaria in areas
where mefloquine- and quinine-resistant strains are endemic (67). In many instances artemisinin
derivatives are used concurrently with mefloquine, quinine, or another antimalarial drug. Artemisinin
combination therapy (ACT) uses artemisinin or its derivatives in combination with other anti-malarial
drugs. Such combinations include, but are not limited to, dihydroartemisinin-piperaquine, artesunate plus
sulphadoxine-pyrimethamine, as well as others. They are administered either orally or intravenously,
depending upon the type of infection and drug combination. These combinations differ in their activity,
but certain combinations are successful in clearing non-complicated falciparum malaria, and even severe
vivax malaria. These combinations have been shown to clear severe vivax malaria faster than chloroquine
alone. ACT activity against P. malariae and P. ovale is high, though ovale (as well as vivax) infections
still require primaquine treatment to prevent relapsing infection. Oral ACT is efficacious against noncomplicated P. knowlesi infection, but intravenous artesunate treatment is used for severe knowlesi (67).
Artemisinin can also act as an anti-cancer, anti-viral, and is effective against a variety of parasitic
diseases. However, its effectiveness in those systems are several magnitudes smaller than in Plasmodium
spp (68).
The mechanism of action of the artemisinins remains a source of fierce debate. It has been suggested that
there are several molecular targets for artemisinin, which include PfATPase6, a sarcoplasmic/ER Ca2+ATPase (SERCA) homolog protein in mammals, translational controlled tumor protein and heme. While
these targets have been proposed, how artemisinin acts on them is also unknown. There is evidence
suggesting these artemisinin protein targets are alkylated, causing downstream affects that lead to parasite
death (69). The mechanism of action is attributed to the endoperoxide bridge (1,2,4-trioxane bridge)
present in the compound, which is activated by either mitochondrial or heme-mediated degradation. The
trioxane bridge has also been implicated as essential for ART’s anti-cancer properties and synergy with
other anti-cancer therapeutics (70, 71). The mitochondrial degradation pathway is responsible for
depolarization of parasite mitochondria and plasma membranes, as well as lipid peroxidation induced
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cytotoxicity via ROS.(72, 73) In heme-mediated degradation, two models have been proposed, but both
models lead to the generation and activation of a carbon centered radical (70, 74). Artemisinin resistance
was observed almost ten years after artemisinin and ACT were implemented in the field. Resistance is
characterized by delayed parasite clearance due to mutations/polymorphisms in the PF3D7_1343700
kelch propeller domain (K13-propeller) on chromosome 13. These mutations lead to increases in
phosphatidylinositol-3-kinase, which is required for the mediations of cell signaling and survival (70).
Further evidence indicates resistance is possibly a cell cycle arrest event, possibly due to prolonged
parasite development at the ring stage where the activation of artemisinin is low, or to DHA induced
dormancy mechanism that is yet to be understood (75, 76).
Methylene Blue and 8-Aminoquinolines
Methylene Blue (MB). Methylene Blue is a synthetic dye that was created in the 19th century by
Heinrich Caro. After its discovery, Paul Ehrlich proposed that it may potentially have anti-malarial
activity in 1891 due to the belief that drugs and dyes might have similar activity against microorganisms
(77). MB was a safe and cheaper treatment for malaria, especially in endemic populations that couldn’t
afford sufficient treatments. It was even found to be safe in G6PD deficient individuals at higher doses
(78). Its use quickly diminished due to the high rates of recrudescence after treatment, as well as the
discovery of more potent anti-malarials. Additionally, MB dyed the eyes blue after treatment. However,
due to the emergence of drug resistant Plasmodium parasites, older compounds like MB are seeing a
revival in drug discovery. MB has many applications in medical therapy. Some of the most notable
applications include visualization of tissues during surgery, treatment of methemoglobinemia, and for
prophylaxis/treatment of ifosfamide-induced encephalopathy that occurs during cancer chemotherapy
(79). MB can be administered via I.V or orally. Studies have shown that the bioavailability is high with
these administrations routes, and that co-treatment with CQ can increase plasma concentrations of MB
(79). The mechanism of action of MB against malaria parasites is due to its ability to act as a “subversive
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substrate”, where it behaves as a redox cycler with glutathione reductase (GSH). One study suggests that
the anti-malarial activity of MB does not inhibit the mitochondrial electron transport chain, and therefore
does not target redox substrates within that system (80). Another aspect of its mechanism of action could
be due to MB’s ability to form free heme/MB complexes. It has been shown that various “sandwich
complexes” of MB with free heme can be formed to interfere with hemazoin biocrystallization, acting in a
similar manner to CQ and other 4-aminoquinolines. This same study also supported the redox cycling
theory of MB’s mechanism of action, showing that it has unique interactions with GSH (81). Other
studies have shown that MB could potentially be effective against drug resistant strains of Plasmodium
due to the lack of cross resistance between MB and other anti-malarials such as CQ, QN and MFQ (82).
Due to the lack of widespread treatment with MB and its lack of robust efficacy against Plasmodium
strains, resistance to MB has not been effectively characterized. However, there is evidence that the
PfCRT is capable of reducing susceptibility to MB, similar to a manner that it confers resistance to CQ
(83). This theory is an especially viable one if you take into account MB’s ability to inhibit hemazoin
formation in Plasmodium; it makes sense that a resistance mechanism to MB would be similar to CQ
resistance.
8-Aminoquinolines: Primaquine and Tafenoquine. The discovery of the 8-AQ class of
compounds as potent anti-malarials began between WW1 and WW2, where thousands of anti-malarials
were being discovered and researched. The first 8-AQ to be discovered was pamaquine/plasmochin. It
was synthesized in 1925, and was found to have anti-gametocyte activity when taken in combination with
quinine (84). Pamaquine’s effectiveness was limited due to its poor schizontocidal activity as well as
causing hemolytic anemia in those with G6PD deficiency, an issue that is consistent among almost all 8AQ analogs. Pamaquine however, lead to the discovery of primaquine (PQ) in 1946. Of the 8-AQs
discovered at this time, PQ was the one that presented the highest efficacy against malaria with the lowest
relative toxicity levels. PQ has enjoyed widespread use for its gametocytocidal activity, as well as its
ability to clear hepatic schizonts and hypnozoite forms for over 70 years (84). During this time, resistance
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to PQ and other 8-AQs has been not been observed to any degree of clinical relevance (85). However, due
to 8-AQs toxicity in those with G6PD deficiency and the increasing prevalence of resistance to other antimalarials, other analogs of PQ have been synthesized. Tafenoquine (TQ) is an 8-AQ analog that is
currently in phase III clinical trials. It was synthesized by scientists at the Walter Reed Army Institute of
Research in 1978. Current development is under GlaxoSmithKline and MMV. The structures of some
prominent 8-AQs can be seen in figure 1.2.

Figure 1.2- Structures of selected 8-AQs. A) Pamaquine, B) Primaquine, and C) Tafenoquine.
PQ is multifaceted, and is used for a variety of reasons. Against malaria, it can be used as primary
prophylaxis against Plasmodium spp., anti-relapse therapy, or as a radical cure when co-administered with
a blood schizonticide. It acts against gametocytes of Plasmodium, and therefore is a very effective antitransmission chemotherapeutic. TQ also enjoys the same properties, but it has been shown to be less toxic
and has better efficacy against erythrocytic forms than PQ (84, 86). PQ has been shown to have activity
against leishmanisis and African trypanosomiasis in vitro, but has not seen any clinically relevant success
against these pathologies (84, 87, 88). PQ also has activity against pneumocystic pneumonia, a fungal
infection that plagues HIV infected individuals. It is given in combination with clindamycin for use as
prophylaxis and treatment. It acts by generating superoxides which interfere with electron transport in
vivo (89). PQ, when used in non-G6PD deficient individuals, is generally well tolerated with a low halflife. It is primarily metabolized in the liver, and is cleared by the kidneys. In those with G6PD deficiency,
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it causes severe hemolytic anemia, which limits its therapeutic uses. G6PD deficiency affects 8% of the
population in malaria endemic countries, where approximately 32.5% of the population in sub-Saharan
Africa and the Arabian peninsula possess it as well (90). Therefore, the need to elucidate the mechanisms
of toxicity and action are considered paramount due to PQs many advantages against Plasmodium that are
not seen in any other anti-malarial.
The mechanism of action of 8-AQ analogs is still a matter of debate. What is known is that their action is
dependent upon metabolites generated in the liver. These metabolites have varied structures such as
hydroxylated forms as well as dimers. Hydroxylated forms are created by the Cytochrome P 450
(CYP450) family of enzymes located in the liver. Previous work has confirmed various isoforms of
CYP450 responsible for metabolite generation, where 2D6 has been implicated in the creation of the
major metabolite responsible for activity (91). However, the specific action of each metabolite and their
targets is still unknown. They could potentially act via multiple mechanisms, though these mechanisms
can’t be adequately studied because of the instability of the metabolites (84). One proposal that has
significant support is the metabolite based generation of ROS species that lead to parasite death. Many of
the reactive metabolites responsible for ROS generation can be seen in Figure 1.4.
The hydroxylated species have been implicated as responsible for generating hydrogen peroxide (H2O2) in
vitro and in vivo. These species are also capable of redox cycling in the presence of an enzymatic system
such as superoxide dismutase, which can go on to generate hydroxyl radicals via downstream effects (92,
93). During normal parasite development, ROS such as H2O2 are natively generated through hemoglobin
metabolism in the parasitophorus vacuole, and through electron transport in the mitochondria. A diagram
of these ROS sources can be seen in figure 1.5. Hydrogen peroxide is primarily responsible for the
majority of ROS mediated stress in Plasmodium spp. Redox regulation is a complex process in
Plasmodium that is mediated by multiple mechanisms. In this context, the most relevant systems would
be the Thioredoxin and glutathione redox cycling systems which are represented in figures 1.6 and 1.7
23

respectively. In the Thioredoxin system, Thioredoxin reductase (PfTrxR) as well as Thioredoxin like
proteins (Trx1-3) are the main proteins responsible for clearance of H2O2. It has also been shown that
Trx1 can act as a backup to the glutathione system by directly reducing oxidized glutathione (94, 95). 8AQs are slightly active against metabolically active asexual stages of Plasmodium, namely the troph and
schizont stages. It is worth noting that the expression of TrxR, as well as Trx proteins, is upregulated in
the troph and schizont stages (96). Since the metabolites of 8-AQs increase hydrogen peroxide
production, it is possible that the anti-oxidant defense of Plasmodium becomes overwhelmed when
exposed to therapeutic concentrations of 8-AQs, resulting in parasite death.
The contention to this theory is that the concentrations required for parasite death are often far above peak
therapeutic concentrations in sera (approx. 0.59 M) (97), which also explains why 8-AQs are not
effective against erythrocytic forms of the parasite without a blood schizonticide. For this theory to
prevail, it would be necessary to determine ROS increases via depolarization potentials in the parasite in
vivo. This would help determine if 8-AQ generated ROS significantly contributes to parasite killing.
Given the fact that 8-AQs are most active against metabolically active stages of Plasmodium infection, it
cannot be denied that 8-AQ mediated ROS production plays a part in 8-AQs anti-malarial mechanism. A
proposed mechanism for PQ metabolite redox cycling can be seen in figure 1.3

Figure 1.3- PQ metabolite redox cycling due to CYP2D6 metabolism. The unstable quinone-imine form is quickly converted to
the more stable 5,6-ortho-quinone. Redox cycling of 5-hydroxyprimaquine is suspected to be primarily responsible for
mechanism of action as well as toxicity.

24

Another proposed mechanism is the inhibition of parasite mitochondrial metabolism via ubiquinone (84,
98). 3H-Primaquine has been shown to accumulate in parasite mitochondria, resulting in mitochondrial
ultrastructure changes. It has also been theorized that metabolic dimers of primaquine are also responsible
for decoupling oxidative phosphorylation in mitochondria, as this has been shown in the rat liver (99).
Furthermore, tafenoquine has been shown to target the respiratory III complex in L. donovani
mitochondria, depolarizing membrane potential in promastigotes leading to apoptosis-like death of the
parasite (84).
It is worth noting that inhibition of mitochondrial function with 8-AQs still leads to ROS production. The
most likely explanation of 8-AQ action, given the various studies, is that it causes excessive ROS
production via metabolite redox cycling and mitochondrial changes. This increase in ROS production
inhibits the parasite’s anti-oxidant defenses while also affecting proper mitochondrial function. Coupled
with an effective blood schizonticide, all parasitic forms are cleared, resulting in a full cure.
PROJECT SPECIFIC BACKGROUND
Discovery and development of new drugs that kill the liver or exo-erythrocytic (EE) stages of malaria,
especially dormant forms (hypnozoites) of P. vivax and P. ovale, requires validated EE models. Current in
vitro EE assays suffer from low throughput, poor correlation with human disease, and limited
development of the liver stages of the major human malaria species. The Kyle laboratory, in collaboration
with the Adams and Draper laboratories at USF, have developed microfluidic devices capable of long
term growth and culture of chimeric mouse expanded human hepatocytes (100). These models are useful
for our purposes in order to investigate mechanisms of action and synergy, and for the definitive detection
of hypnozoite forms of P. vivax or ovale. While there is evidence for these forms in zoonotic species of
Plasmodium (like in P. cynomolgi), hypnozoites of P. vivax or ovale have yet to be validated due to the
nature of hepatic infection. Sporozoites select for certain hepatocytes before beginning infection, and can
kill hepatic cells they pass through on their journey. The deaths of these hepatocytes, while
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inconsequential in vivo, have devastating consequences in in vitro models. The entire culture system can
become compromised due to the death of these select hepatic cells. These microfluidic devices can allow
us to culture liver stage infection in vitro, and attempt to perform various experiments determining the
nature of these forms and therapeutics effective against them.
8-AQs are effective against late stage (IV-V) gametocytes as well as hepatic schizonts of Plasmodium
infection, but are only mildly effective against asexual blood stages (84, 86, 101). Therefore, to fully clear
Plasmodium infection, 8-AQs are often given with a blood schizonticide such as CQ or artemisinin based
compounds. Studies have found that synergy between CQ and PQ is attained in Plasmodium infection
(102), though the mechanism of this synergy isn’t adequately understood. Understanding this synergy
could assist in finding novel therapeutics and combinations in order to treat drug resistant Plasmodium
infection. Investigating this phenomenon isn’t possible with standard anti-malarial assays, as CQ is not
effective against liver stage infection. Therefore, another approach is needed to understand CQ’s role in
synergy against liver stage infection. Pharmacological studies of drugs using fluorescent tags have long
been a method of determining the mechanisms of action, synergy, and resistance (103). These methods
have seen use in anti-malarials as well (56, 73). Using these microfluidic devices, as well as tagging 8AQs with fluorescent tags, we can potentially elucidate the mechanism of synergy by observing
differential accumulation of each drug in infected hepatocytes.
FOCUS OF STUDY
This study seeks to synthesize, characterize and investigate the effects of novel 8-AQ fluorescent probes
on Plasmodium infection. These probes will then be used to examine accumulation of each drug in
hepatocytes infected with Plasmodium. With this information, we can propose a mechanism of synergy
and enhance the knowledge of the activity of 8-AQs.
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Figure 1.4- Hydroxylated metabolites of PQ. These forms are suggested to be implicated in PQ mechanism of action. In
addition to 5-hydroxyprimaquine (8), these metabolites are suspected of also undergoing redox cycling to facilitate parasite
killing.
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Figure 1.5- Sources of ROS in Plasmodium infection. Notice how redox cycling due to Thioredoxin occurs in the cytosol.
Superoxide Dismutase (SOD) is primarily responsible for hydrogen peroxide production in the cytosol.
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Figure 1.6- Thioredoxin system in Plasmodium. The redox cycling in this system influences the regulation and production of
hydrogen peroxide, along with activating protein targets and regulating peroxiredoxins.
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Figure 1.7- The glutathione system in Plasmodium. Redox cycling of GSSG to GSH also influences ROS regulation and
production via the Thioredoxin system Trx-SS and Trx-(SH)2. GSH is an important redox regulator in Plasmodium.
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CHAPTER 2-SYNTHESIS AND CHARACTERIZATION OF NOVEL 8-AMINOQUINOLINE
FLUORESCENT PROBES
INTRODUCTION
Current therapeutics to clear liver stage infections in ovale and vivax malaria include atovaquone and 8aminoquinolines (primaquine, tafenoquine, pamaquine, etc.), though atovaquone does not clear
hypnozoites or gametocytes in blood stages (43, 104). Primaquine and tafenoquine are within the 8aminoquinoline class of compounds to which Plasmodium has little observed resistance. It is worth noting
that despite 8-AQ resistance not being readily observed, the criterion for parasitic resistance against these
molecules is still undefined (104, 105). These molecules not only exhibit some moderate asexual stage
activity, but are also effective against sexual stages (Stage III-V gametocytes), hepatic schizonts, and
hypnozoites (84).
Coumarin is an organic benzopyrone molecule that was discovered in 1820 by German chemist Alfred
Vogel. Vogel discovered coumarin by isolating it from Tonka beans and sweet clover. Its formal
synthesis wouldn’t be described until 1868 by William Henry Perkin, who also discovered the Perkin
reaction to synthesize cinnamic acids. The 7-hydroxy and 7-methylamino substituted coumarin molecules
have significantly higher quantum yields than the coumarin moiety alone. They are often employed as
fluorescent probes, enzyme substrates, or in bio-conjugation reactions (106). Other derivatives of
coumarin have found medicinal applications as well (107). Coumarin synthesis can be accomplished
multiple ways, but the most often used synthetic route is the Pechmann condensation, which uses a
phenol and a carboxylic acid or ester that has a -carbonyl group. The basic reaction conditions for the
Perkin reaction and Pechmann condensations can be seen in figure 2.1. Coumarin versatility in reaction
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synthesis, use in fluorescence studies, extensive characterization, and biomedical application made it an
attractive choice for our purposes.

Figure 2.1- Examples of A) Perkin reaction and B) Pechmann condensation. Pechmann condensation is one of the many ways
to synthesize coumarin molecules.

Synthesis of fluorescent analogs of chemotherapeutics has recently gained interest for various
applications. These analogs can offer much information about the drug’s mode of action, resistance, and
even basic science of the pathogen which it acts against. Using fluorescent drug labeling has found use in
studying cancer therapy mode of action. Various methods are exploited to study fluorescence localization,
and can even use these dyes as an indication of drug release and efflux (108). For malaria, probes of
chloroquine and artemisinin have been synthesized, characterized and investigated to give information
about parasite biology, as well as mechanisms of action and resistance for both chloroquine and
artemisinin. Fluorescent chloroquine analogs have been used to study chloroquine influx and efflux
kinetics to determine how chloroquine action differs in CQ sensitive vs resistant parasites (56), and to
examine how P-glycoprotein inhibition affects malaria parasites in vitro (109). Both of these studies use
different analogs, yet exploit the same localization methods and theory to determine both
pharmacokinetics of chloroquine as well as basic biology of Plasmodium parasites. Furthermore, a novel
artemisinin fluorescent analog was used to investigate artemisinin localization in live parasites, as well as
provide more evidence linking artemisinin mechanism of action to the 1,2,4-trioxane bridge characteristic
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of artemisinin analogs (73). These studies effectively demonstrate the value in using fluorescent analogs
of drugs to further their characterization against infections of various types.
While probes of chloroquine and artemisinin have been synthesized, various probes of 8-AQ molecules
have not. Fluorescent co-localization studies of these 8-AQ probes with chloroquine probes could provide
evidence for why these various compound combinations (PQ/CQ and TQ/CQ) have synergistic activity in
asexual stages (102). Additionally, because of 8-AQ effectiveness against liver stages, we can potentially
use fluorescent probes of these molecules to help detect liver stage forms, and potentially hypnozoite
forms. Coumarin was chosen as the probe of choice due to its extensive characterization and fluorescent
intensity, as well as its limited areas of reactivity. These properties allowed us to create reaction schemes
that exploited this limited reactivity in order to couple it to primaquine and tafenoquine.
In this study we demonstrate the synthesis and chemical characterization of the novel primaquinecoumarin probe (PQCP) and tafenoquine-coumarin probe (TQCP). There were two synthetic schemes
proposed for the synthesis of PQCP. The first scheme will be discussed, but ultimately resulted in failure
to obtain the final product. Specific experimental details will be omitted for coherence and clarity. The
second scheme vastly improved upon the first, and the differences between the two will also be discussed.
The 1H-NMR, High Resolution Mass spectra, as well as quantum yields have been determined for both
probes, though PQCP was used as the mainstay probe for in vitro experiments due to incomplete
characterization of TQCP.
MATERIALS AND METHODS
PQCP synthesis
Compound 1 was synthesized in house by methods previously described (110, 111). PQCP [2] and
TQCP [3] were synthesized by utilizing the EDCI/Dmap coupling reaction. Primaquine bis-phosphate
(Sigma-Aldrich, St. Louis, MO) was combined with excess (3-4eq) NaOH and stirred at room
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temperature for 30min-1hr (reaction not shown). The free base form of Primaquine was extracted twice
with DCM. LC-MS analysis displayed a single chromatogram peak. The dark vicious liquid was used
without further purification. A flame dried, round bottom flask filled with argon via balloon was charged
with free base 8-aminquinoline (1eq), 4-(7-hydroxy-2-oxo-2H-chromen-4-yl) butanoic acid (1eq) and
toluene (3ml). The toluene was evaporated under reduced pressure. EDCI (2eq) and Dmap (20mol%) was
added to the flask, and the flask was recharged with argon via balloon. DCM was added via syringe
through a rubber septum. The reaction was stirred at room temperature for 18 hours. The mixture was
extracted twice with ethyl acetate and dried over anhydrous sodium sulfate. The mixture was then
concentrated onto silica gel, and purified via flash chromatography. Effort was taken to make sure the
reaction and fractions had minimal light exposure. Fractions were analyzed via LC-MS for pure product.
Pools containing pure compound were concentrated resulting in green crystals (78%). 1H-NMR PQCP
(400 MHz, Acetone-d6): δ 9.40 (s, 1H), 8.47 (q, 1H), 7.99 (dd, 1H), 7.68 (d, 1H), 7.34 (q, 1H), 7.18 (s,
1H), 6.81 (dd, 1H), 6.71 (d, 1H), 6.42 (d, 1H), 6.28 (d, 1H), 6.11 (d, 1H), 6.01 (s, 1H), 3.83 (s, 3H), 3.68
(m, 1H), 3.26 (m, 2H), 2.75 (t, 2H), 2.29 (t, 3H), 2.03 (m, 2H), 1.95 (m, 2H), 1.66 (d, 2H), 1.27 (d, 2H).
[M+H]=490.2349
TQCP synthesis
A flame dried, round bottom flask filled with argon via balloon was charged with Tafenoquine Succinate
(1eq), 4-(7-hydroxy-2-oxo-2H-chromen-4-yl) butanoic acid (1eq) and toluene (3ml). The toluene was
evaporated under reduced pressure. EDCI (2eq) and Dmap (20 mol%) was added to the flask, and the
flask was recharged with argon via balloon. DCM was added via syringe through a rubber septum. The
reaction was stirred at room temperature for 18-24 hours. The mixture was extracted twice with ethyl
acetate and dried over anhydrous sodium sulfate. The mixture was then concentrated onto silica gel, and
purified via flash chromatography. Effort was taken to make sure the reaction and column
chromatography fractions had minimal light exposure. Pools containing pure compound were
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concentrated resulting in yellow/golden crystals (50%). TQCP 1H-NMR (400 MHz, Acetone-d6): Unable
to determine. [M+H]=694.2761
Absorbance Spectra and Steady State Emission Studies
The absorption spectrum of each compound was obtained using a Shimadzu UV2401 spectrophotometer.
Samples were placed in a 1-cm quartz optical cuvette in ethanol and spectra were obtained form 200-500
nm. Steady state emission spectra were obtained using an ISS PC1 single photon counting
spectrofluorimeter using a 600W Xe arc lamp as the excitation source.
RESULTS
The first generation scheme of synthesis can be seen in figures 2.2-2.4. In this first scheme, we had a 3
step approach. First we sought to synthesize the linker compound first then couple the linker to coumarin.
After the coumarin-linker compound was made, we would then couple it to primaquine or tafenoquine.
This scheme was inefficient for several reasons. The first is that too many groups required chemical
protection, decreasing the overall efficiency of the synthetic scheme. BOC protection of the primary
amine group in the linker analog had to be maintained throughout the reaction procedures, and adds two
reactions to the overall scheme, leaving room for product loss. Additionally, when the final reaction
initially encountered difficulty, further protective groups were added to the bromo-coumarin analog to
prevent side reactivity. Despite this protection, the final reaction still didn’t proceed; LCMS detected less
than 2% product formation after 24 hours of reaction time. More rigorous reaction methods could not be
pursued due to increased potential of side product formation.
Secondly, some reactions had side products that couldn’t be separated from the main product without
extensive, laborious purification methods. The initial synthesis of the bromo-coumarin analog via H2SO4
provided little product formation. This was due to a side product being formed that couldn’t be purified
from the main product without extensive time consuming methods. To combat this issue, synthesis of the
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bromo-coumarin analog was done via microwave synthesis, as described (107). Microwave synthesis
offered many benefits, including minimal reaction times (<30min). The minimization of reaction time
allowed faster screening of optimal conditions to obtain viable product. Another advantage is that side
product formation with these conditions was less of a hindrance to purification than the H2SO4 route.
Despite all the advantages of microwave synthesis, including adequate yields of product, difficulties with
this reaction scheme continued.
Lastly, the final alkylating step simply did not work, despite screening several different bases at varying
concentrations, as well as varying temperature. The temperatures, bases used and their stoichiometric
equivalents can be seen in Table 2-1. These varying methods either resulted in little to no product after
24hrs of reaction time. It is believed that this was due to the linker chain between coumarin and
primaquine being too long, though no experiments were conducted to verify or refute this idea.
Table 2-1- Various screening conditions for EDCI/Dmap coupling of the primaquine-linker compound to coumarin.

Bases

Stoichiometric equivalent

Temperature (0C)

DIPEA

0.5, 1.0, 1.2, 2.0

0, 25

K2CO3

0.1, 0.5, 1.0, 1.2, 2.0

0, 25

Cs2CO3

0.1, 0.5, 1.0, 1.2, 2.0

0, 25

This led to the generation of the second scheme. This scheme worked much better overall, and can be
seen in Figure 2.5. The amounts of steps, as well as purifications, were cut almost in half. Additionally,
there was no need for protection reactions, as the coumarin-linker compound was formed in a single step.
The final alkylation reaction also proceeded easily, with a minimum 50% yield. Since the new coumarinlinker compound readily reacted with the primary amine group of primaquine, this led us to believe that
the final reaction in the previous scheme failed due to a longer linker length, since that is the only
difference between the final products.

36

For the second reaction scheme, the synthesis of the -keto ester via Meldrum’s acid was described (110,
112). The addition of the acyl chloride must be done slowly, otherwise side products are easily formed,
making purification more difficult. The intermediate formed with meldrum’s acid can be isolated via
purification, but is usually not necessary. In this study, methanolysis was done immediately after the
detection of the product by LC-MS and removal of residual reactants and solvent. After synthesis of the
-ketoester, the coumarin moiety was synthesized as described (106). For this reaction, the coumarin
synthesis and subsequent hydrolysis were also done without further purification of the intermediate.
Synthesis of the coumarin moiety and the subsequent fluorescent primaquine (and tafenoquine) molecule
was done under limited light exposure to prevent photobleaching and maintain fluorescence. To
accomplish this, the lights in the hood were turned off and the columns along with any fractions were
wrapped with aluminum foil. Product concentration under reduced pressure was also done with the
product vial wrapped in foil.
While electron spray ionization mass spec effectively characterized both probes, molecular
characterization via NMR was hindered for TQCP. Due to limited amounts of product and the presence of
the –CF3 group on TQ, initial 1H-NMR characterization as well as 13C-NMR characterization was
inconclusive. 1H-NMR studies using between 1-5mg of TQCP were inconclusive. We attempted to use up
to 10mg of TQCP to obtain spectra. While we did obtain a moderately good 1H-NMR for TQCP, 13CNMR for both probes was unable to be analyzed in our hands. For this reason, in addition to concerns
about fluorescence shelf life, we attempted to further characterize the probes via fluorescence and
absorption spectroscopy.
The absorption spectra of PQCP and TQCP together with the parent PQ, TQ and coumarin are displayed
in Fig. 2.10. The spectra for PQ and TQ are dominated by bands at ~265 nm and ~360 nm originating
from a transition from the So to 1LB state and 1LA state, respectively. The 1LB state is a bond centered state
with excess charge density on the quinolone ring while the 1LA state is an atom centered excess charge
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density state with the excess charge density localized on the heterocyclic nitrogen. The spectrum of
coumarin contains a single transition centered at 320 nm that arises from a strongly allowed *
transition overlapping with a weaker n-* transition. The absorption spectra of the PQCP and TQCP
complexes are essentially the sum of the PQ/TQ and coumarin spectra indicating that there are no
intramolecular interactions between the ring systems of the two chromophores within the complexes.
The corresponding steady state emission spectra of PQ, TQ, PQCP, TQCP and coumarin are displayed in
Fig. 2.11. Excitation of PQ at 320 nm results in an emission spectra with a maxima centered at 465 nm
and is due to the radiative relaxation from the 1LA excited state while excitation of coumarin at 320 nm
results in an emission maxima centered at 380 nm arising from relaxation from the 1S1 excited state. As
the absorption spectrum of the PQCP complex is dominated by the coumarin chromophore in the region
of 300 nm to 350 nm, excitation of the complex at 320 nm results in an emission spectrum that is nearly
identical to that of the isolated coumarin with only a small shoulder at 450 nm arising from the PQ
chromophore. The TQ molecule exhibits an emission spectrum similar to PQ upon 320 nm excitation.
However, excitation of the TQCP complex results in an emission spectrum with a much greater
contribution from the TQ chromophore which is likely due to the presence of a weak absorption band
associated with TQ that is not present in PQ.
CONCLUSION
The synthesis and characterization of a novel fluorescent 8-AQ probe has been described. The synthesis
of these probes proceeds readily from previously synthesized coumarin analogs via -keto ester routes.
Care must be taken to ensure light protection after coumarin analogs have been created. The presence of
CF3 groups hinder effective proton and carbon NMR characterization of tafenoquine based probes; much
product is required in order to obtain adequate spectra (>10mg). While its fluorescence is not as strong as
coumarin alone, it is sufficient for in vitro studies. In order to ensure success of future microscopy
analysis, their anti-malarial activity will be assessed to make sure it doesn’t differ from the parent
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compound (PQ). Cytotoxicity assays against human hepatoma cell line HepG2 will be done to ensure the
probes do not kill the host cells before entering the liver stage parasite. Finally, we will construct
methods for PQCP co-localization studies with other commercially available probes, and then determine
their localization in erythrocytic and exo-erythrocytic forms. Detection of these forms in erythrocytic
stages (sexual and asexual) could even give information about mechanism of action if they localize to any
specific receptors or organelles. If these probes prove to be viable in detecting exo-erythrocytic forms, it
could give us information about the mechanism of action against hepatic schizonts and hypnozoite forms.
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Figure 2.2- Synthesis of the PQ-linker compound. Reactions with an ‘x’ over the arrow either didn’t proceed to completion, or
the product was unable to be isolated.
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Figure 2.3- Synthesis of the bromo-coumarin moiety. Pechmann condensation yielded minimal product in this study and was
abandoned, as indicated by the ‘x’ reaction. Microwave synthesis was employed to create the bromo-coumarin intermediate
with adequate yields (50%).
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Figure 2.4- Failed reaction of PQ-linker with bromo-coumarin intermediate. It is believed this reaction did not proceed due to
the extended linker chain. Attempted basic conditions for this reaction are listed in Table 2.1
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Figure 2.5- Second generation synthesis of PQCP (2) and TQCP (3). Compound (1) was synthesized by previously described
methods. The EDCI/Dmap coupling reaction proceeded readily for both reactions (50-60% yield).
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Figure 2.6- Experimental details of the electron spray ionization (ESI) high resolution mass spec of PQCP. The same procedure
and instrumentation was used for TQCP.

44

Figure 2.7- ESI High resolution mass spectra of TQCP.
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Figure 2.8- 1H-NMR of PQCP.
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Figure 2.8- 1H-NMR of TQCP
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Figure 2.10- Normalized optical absorption spectra of PQ, PQCP and coumarin (Panel A) and TQ, TQCP and coumarin (Panel B).
The concentrations of each compound were ~15-20 µM in 2 mL of ethanol. Spectra were obtained in a 1-cm quartz optical
cuvette.
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Figure 2.11- Normalized steady state emission spectra of PQ, PQCP and coumarin (Panel A) and TQ, TQCP and coumarin
(Panel B). The concentrations of each compound were ~5 µM in 2 mL of ethanol. Spectra were obtained in a 1-cm quartz
optical cuvette. Excitation- 320 nm.
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CHAPTER 3: IN VITRO CHARACTERIZATION OF 8-AMINOQUINOLINE FLUORESCENT
PROBES
INTRODUCTION
8-Aminoquinolines are a class of anti-malarial compounds that have great efficacy against sexual stages
and moderate activity against asexual stages. The mechanism of action of these molecules is dependent
upon their metabolites, and various investigations support this theory (91, 113). After undergoing various
metabolic reactions, the reactive metabolites interact with the parasite causing death. How these reactive
metabolites clear Plasmodium parasites is not completely understood, though it is believed that these
metabolites induce intracellular oxidative potentials that lead to parasite death (84, 114). When combined
with a blood schizonticide such as chloroquine, the combination acts as a radical cure, clearing the
infection. 8-aminoquinoline use is limited due to toxicity in those with glucose 6-phosphate
dehydrogenase deficiency, where hemolytic anemia occurs with varying severity. It is possible that the
mechanism of action and the mechanism of toxicity are interlinked, and there is evidence suggesting that
the mechanism of toxicity could be mediated by various groups substituted on the 5-position of the
aminoquinoline ring system(115). Understanding these mechanisms is important, as they could indicate
why Plasmodium has not developed an effective resistance to these compounds.
Fluorescent localization studies of Plasmodium parasites, as well as other diseases, can offer a host of
information about microorganism biology, as well as the mechanism of action of particular therapeutics.
While much of Plasmodium biology has been characterized and readily understood, definitive detection
of hypnozoite forms remains elusive. Various studies have confirmed their presence in zoonotic
Plasmodium species such as P. cynomolgi and P. simiovale (116), and this is often used as evidence for
the existence of hypnozoites in human infections with vivax and ovale. The difficulty in hypnozoite
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detection lies in hypnozoites’ limited metabolism and cell cycle functions, keeping them from being
detected by methods that exploit those functions. Difficulty in detection is compounded by the fact that
hypnozoites appear in very limited numbers when actually found in cynomolgi and simiovale.
Additionally, human hepatocytes are hotbeds of cytochrome P450 enzyme activity, many of which are
fluorescently active. This auto-fluorescent activity adds considerable background to fluorescence
microscopy, making detection of some fluorescent probes difficult when searching for hypnozoites.
Very recently, a transcriptome study of hypnozoites from P. cynomolgi was accomplished via laser
capture microdissection. This study was the first to describe gene regulation in hypnozoites and
effectively compare them to blood and liver stage forms. It was found that hypnozoite quiescence is
possibly regulated by the ApiAP2 family of transcription factors, and translational repression by the elF2a
kinase elK2 (117). While this work is a huge step forward in the characterization of hypnozoites, effective
detection of the vivax and ovale forms remains elusive.
This study investigates the in vitro characterization of these novel 8-AQ fluorescent probes. Though their
anti-malarial and anti-leishmaniasis activities significantly differ from their parent molecules, the IC50
concentration values are similar in terms of magnitude. They are not toxic against HepG2 carcinoma
cells, and their localization in asexual and sexual stage parasites is cytosolic. Co-localization studies
indicate there is no mitochondrial localization, though this is most likely due to the bulky nature of the
PQCP/TQCP molecules.
MATERIALS AND METHODS
Culturing of P. falciparum parasites and in vitro cultures
P. falciparum parasite strains 3D7, W2 (Indochina), D6 (Sierra Leone), and D10 (ATCC) were
maintained in culture as previously described(118). All cultures were supplemented with 4% O+ human
red blood cells (Interstate Blood Bank, Memphis, TN), 10% heat inactivated A+ human plasma (Interstate
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Blood Bank), and RPMI1640 media supplemented with 25mM HEPES(Sigma-Aldrich). D10 parasite
cultures were supplemented with 100 nM Pyrimethamine in order to select for GFP parasites. For
fluorescent microscopy and drug susceptibility assays, cultures were synchronized to ring stage using 5%
(w/v) D-sorbitol (Sigma-Aldrich, St. Louis, MO) as described (119). Growth staging was determined by
geimsa staining and light microscopy.
Characterization of Anti-malarial Activity in asexual stages
Anti-malarial activity assays performed against P. falciparum clones 3D7, W2, and D6 were performed
using a modified 3H-Hypoxanthine uptake assay (120). Initial drug stocks were prepared in DMSO. All
final drug dilutions were prepared using RPMI1640 media supplemented with 25 mM HEPES. Drugs
were serially diluted 1:2 with a starting concentration of 100g/ml. Drug susceptibility curves and IC50s
were calculated using GraphPad 6 software.
L. donovani axenic amastigotes assay
Compounds were tested against L. donovani axenic amastigotes (MHOM/SD/75/1246/130) using the
CellTiter 96 Aqueous one-solution cell proliferation assay (Promega, Madison, WI). In a 96 well drug
plate (Costar, Assay Plate, 96 well with low Evaporation Lid, Flat Bottom, None-Treated, #3370)
compounds were diluted in a series of 6 2-fold dilutions in media to produce a concentration range from
200μg/ml to 6.25μg/ml. Ten μL from each well was transferred to another 96 well plate (Costar, Assay
Plate, 96 well with low Evaporation Lid, Flat Bottom, Tissue culture Treated, # 3628) and then 90uL of
parasites in media in a 66,000 cell per well concentration was added to produce a final concentration
range from 20μg/ml to 625ng/ml. The plates were then incubated at 37oC for 72 hours. Twenty μL of 3(4,5-dimethylthiazol-2-yl)-5(3-carboxymethoxyphenyl)-2-(4-sulphophenyl)-2H-tetrazolium (MTS:
Promega, Madison, WI) solution was added to each well and incubated for an additional 4 hours. A
Spectra Max M2e (molecular Devices, Sunnyvale, Ca) was used to measure optical density (OD) at
490nm.
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L. donovani cytotoxicity assay
Compounds were tested against J774.A1 macrophages using the CellTiter 96 Aqueous one-solution cell
proliferation assay (Promega, Madison, WI). In a 96 well drug plate (Costar, Assay Plate, 96 well with
low Evaporation Lid, Flat Bottom, None-Treated, #3370) compounds were diluted in a series of 6 2-fold
dilutions in media to produce a concentration range from 500μg/ml to 15.625μg/ml. Ten μL from each
well was transferred to another 96 well plate (Costar, Assay Plate, 96 well with low Evaporation Lid, Flat
Bottom, Tissue culture Treated, # 3628) and 90μL of macrophages in media in a 50,000 cell per well
concentration was added to produce a final concentration range from 50μg/ml to 1.562 μg/ml. The plates
were then incubated at 37oC, 5% CO2 for 72 hrs. Twenty μL of 3-(4,5-dimethylthiazol-2-yl)-5(3carboxymethoxyphenyl)-2-(4-sulphophenyl)-2H-tetrazolium (MTS: Promega, Madison, WI) solution was
added to each well and incubated for an additional 4 hours. A Spectra Max M2e (molecular Devices,
Sunnyvale, Ca) was used to measure optical density (OD) at 490nm.
Hepatocyte culture
Frozen HepG2 hepatocytes (ATCC) were cultured on rat tail-1 collagen coated 75cm2 vented flasks in
media containing: Eagle’s Minimum Essential Medium with 10% fetal bovine serum, 1% L-glutamine
additional supplement, and 1% Penicillin-Streptomycin. Cultures were incubated in a mixed gas incubator
at 37°C. Cultures receive media change within the first 24 hours post-seeding from cryopreservation stock
and media renewal every other day.
Animals and Parasites
All mice used in these experiments were female BALB/c mice obtained from Envigo (Indianapolis, IN).
The transgenic P. berghei line 1052 Cl1 (Pb 1052 Cl1) used in the liver stage assay was obtained from
C.J. Janse at Leiden University. This line was generated from the reference clone of ANKA strain
c1115cyl and was designed to express a green fluorescent protein (GFP) and firefly luciferase. Pb 1052
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Cl1 has two copies of the GFP-luc integrated into its genome. One copy is under the control of a
constitutively expressed eef1aα promoter, and the other is under the control of an ama1 promoter. This
study was conducted in compliance with the Guide for the Care and Use of Laboratory Animals of the
National Research Council for the National Academies. The protocol was approved by the University of
South Florida Institutional Animal Care and Use Committee.
Cytotoxicity of PQCP/TQCP in HepG2 cells
HepG2 cells were used for cytotoxicity assays once they reached >90% confluence. Afterwards, cells
were trypsinized, counted, and seeded into collagen coated 96 well plates at 35,000-40,000 cells per well.
Cells were allowed to adhere overnight at 37 0C. Dilutions of PQ, TQ, TQCP, and PQCP were made and
added to plates, with an initial concentration of 125g/ml. 1:2 serial dilutions were made, with a final
concentration of 0.122g/ml. After the compounds were added the plate was incubated at 37 0C for 24
hours. After this period, cell viability was assessed by MTS [(3-(4,5-dimethylthiazol-2-yl)-5-(3carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium)] cell proliferation assay (CellTiter96
Aqueous non-radioactive cell proliferation assay, Promega Corp., Madison, WI). Plates were read using a
SpectraMax M2e (Molecular Devices, Sunnyvale, Ca) at 490 nm wavelength. IC50 calculations and
cytotoxicity curves were created using GraphPad 6 software.
Fluorescent Microscopy of sexual and asexual stage parasites
PQCP and TQCP were synthesized as described. Mitotracker Red (MTR) and SYTO11 were obtained
from Thermo-Fisher. Cultures were grown and maintained in a similar manner described above, with the
exception of being grown in RPMI1640 complete media without phenol red. Cultures of D10 or W2
parasites were allowed to grow to 2-6% parasitemia for screening. For primaquine saturation experiments,
150 M PQ was incubated with the parasites and washed before fluorescent probes were added.
Infected erythrocytes (0.1% HCT) were washed with phenol red free RPMI1640, then incubated with
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7.5nM MTR, 1 M SYTO11, and 150 M PQCP/TQCP for 30-45min in 12 well plates. After
incubation, cells were spun at 1850rpm for 2min. The supernatant was removed and erythrocytes were
immersed in 200 l RPMI and allowed to incubate for another 30-45min. After this incubation, cells were
re-suspended and transferred to 8 chamber slides for visualization. Pictures were taken using the
Deltavision inverted fluorescence microscope (GE Life Sciences, Pittsburgh, PA) with the 100x objective.
Statistical Analysis
All statistical analysis was carried out using Graph Pad Prism 6 software (GraphPad Software Inc., La
Jolla, CA). Data for anti-malarial, anti-leishmaniasis, and cytotoxicity assays were normalized against
minimum negative control values and maximum positive control values. All values are expressed as
means and standard deviations (SD). A  <0.05 was considered statistically significant. Data was
analyzed using non-linear regression and a comparison of fits test to determine significant differences in
drug action.
RESULTS
Coumarin does not affect 8-AQ anti-leishmanisis or anti-malarial efficacy in asexual or liver stage
infection
Studies of PQCP and TQCP vs the parent compounds PQ and TQ indicate that the addition of the
fluorescent coumarin moiety does not adversely affect compound efficacy. In 3H-Hypoxanthine assays
with various strains of P. falciparum (3D7, W2, D6), no significant differences in IC50 values were
observed between PQ/PQCP and TQ/TQCP. A similar phenomenon occurs in L. donovani as well.
Figures 3.1-3.3 and 3.5 shows dose response curves of their activities vs the respective strains and
parasites.
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PQCP localizes in the cytosol of P. falciparum asexual parasites
In our evaluation of localization, figure 3.6 displays PQCP localization in the various asexual stages
(Ring, Troph and Schizont) while fig 3.7 displays stage IV and V gametocytes. The pictures display
localization of PQCP as mainly cytosolic. Co-localization of these probes with GFP and mitotracker also
suggests that primaquine does not directly act upon the apicoplast or the mitochondria, due to lack of
overlapping fluorescent signals. Parasites pre-loaded with primaquine support cytosolic localization, as
PQCP fluorescence is not observed when parasites are saturated with PQ.
TQCP and PQCP are not toxic to HepG2 cells
In order to make sure the probes do not adversely affect hepatic viability, we performed cytotoxicity
assays using HepG2 human carcinoma cells. The probes were again screened against the parent
compounds of PQ and TQ. There were significant differences in IC50 values between PQ/PQCP pair and
the TQ/TQCP pair. The fluorescent probes were significantly less toxic than the parent compounds. We
believe this is because the bulky probes have a more difficult time being taken up by uninfected
hepatocytes.
DISCUSSION
Addition of the coumarin moiety to primaquine and tafenoquine had interesting effects on their in vitro
activity. Despite significantly increasing the size of the molecules, the anti-malarial and anti-leishmaniasis
activity didn’t greatly differ from the parent molecules, and the differences in IC50 were not statistically
significant in most cases. It is possible that adding the coumarin moiety to TQ, along with the metatrifluoromethyl-phenoxy group at the 5 position, affects trafficking and metabolism respectively. These
two factors could be the reason why such a drastic difference is seen in the TQ/TQCP pair vs the
PQ/PQCP pair in cytotoxicity, as well as anti-malarial activity in the W2 strain of P. falciparum. It is
expected that trafficking of the molecule would be impacted given such a drastic change to the parent
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molecule. Regardless, the activities remain similar for the PQ/PQCP pair throughout the anti-malarial and
anti-leishmaniasis assays. This could potentially mean that metabolism at the terminal amine in the PQ
chain isn’t necessary for anti-malarial activity. It has even been theorized that blocking the primary
terminal amine in PQ could help its bioavailability by blocking the conversion to carboxyprimaquine (84,
121). However, whether or not the coumarin-linker modifier has this effect has not been investigated. The
difference in cytotoxicity against HepG2 cells is more affected by the addition of the coumarin moiety.
The probes are less toxic than their parent molecules, though they are still somewhat cytotoxic. Again, it
is possible that the addition of the coumarin moiety affects molecule transport into and out of HepG2
cells. We attempted to determine localization of the probes in HepG2 cells, but background fluorescence
of cytochrome enzymes prevented effective characterization of PQCP localization in uninfected HepG2
cells.
Despite the decrease in fluorescent intensity compared to coumarin, fluorescence is still maintained in in
vitro culture and experiments. The concentrations needed for effective fluorescence are much higher
when compared to commercialized probes such as mitotracker red (100 M vs 1 M respectively). This
will perhaps limit the use of the probe in localization and trafficking studies, as over-exposure can
increase parasite stress leading to lysis and death. Regardless, fluorescent localization can be effectively
observed in both P. falciparum and L. donovani parasites. In falciparum, localization of PQCP appears to
be limited to the cytosol of the parasite. This specific localization was further confirmed by saturation
experiments with PQ, as well as co-localization studies with mitotracker red. Previous work with 3Hprimaquine indicates that PQ localization also occurs in the mitochondria (99). The lack of localization of
PQCP in mitochondria is most likely due to the presence of the coumarin moiety on the probe itself.
We also investigated the co-localization of the nuclear stain SYTO11 with PQCP. Coumarin and
therefore PQCP/TQCP fluoresce as blue, so traditional nuclear stains such as Hoechst couldn’t be used. In
order to determine localization with a probe that stains nucleic acids, we employed SYTO11 as a control
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probe to elucidate nuclear localization. Unfortunately, SYTO11 localization is primarily cytosolic, and
overlapped with PQCP. The use of SYTO11 didn’t adequately detect the nucleus, so we decided to use
the D10 strain of P. falciparum, which has a GFP tag on the ACL protein which localizes to the
apicoplast. This proved to be especially effective in our co-localization studies, as PQ and TQ have not
been implicated as having any apicoplastic targets.
Again, addition of the coumarin moiety would consequently affect trafficking. It is possible that the
channel responsible for PQ efflux into parasite mitochondria isn’t able to transport PQCP as effectively
and localization isn’t observed as a result. Nevertheless, cytosolic localization with no co-localization in
the apicoplast or mitochondria could indicate PQ has a cytosolic target which affects its mechanism of
action. Kimura et al have proposed PfPdxK as a target for PQ (97). Given the potential of PfPdxK as a
target, as well as previous work indicating PQ affects SOD in Plasmodium due to increases in H2O2
production (84, 92, 93), cytosolic localization appears consistent with a mechanism that has PfPdxK as
well as SOD as molecular targets. Similar localization phenomenon is observed in stage IV-V
gametocytes, though more co-localization studies are needed in order to definitively define PQCP
localization.
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Figure 3.1- 3H-Hypoxanthine concentration response curves for TQ and TQCP against 3D7, W2, and D6 strains of P.
falciparum. Similar curves indicate similar activity between compounds.
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Figure 3.2- 3H-hypoxanthine concentration response curves of PQ/PQCP against 3D7, W2, and D6 strains of P.
falciparum. Similar curves and statistical analysis of IC50s indicate no significant differences in drug action.
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Table 3.1-IC50s of PQ, PQCP, TQ, and TQCP against various strains of P. falciparum
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Figure 3.3- Activity of PQ/PQCP against L. donovani axenic amastigotes. Similar curves and statistical analysis suggest no
significant differences in drug action in this system.
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Figure 3.4- Cytotoxicity assay of PQ/PQCP and TQ/TQCP against HepG2 Carcinoma cells. No
significant differences in cytotoxicity were observed in the dosing pairs.
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Figure 3.5- Anti-malarial activity of PQ/PQCP and TQ/TQCP against P. berghei in the
liver model. TQ/TQCP variability in one of the experiments causes the curves to appear
to be different, but statistical tests suggest there are no significant differences in IC 50s
between the two pairs.
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MERGE
Figure 3.6- Images of D10 P. falciparum parasites treated with 150 M PQCP and 1 M MTR. Green channel is Green
fluorescent protein tagged to the ACL carrier protein targeted to the apicoplast.
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Figure 3.7- Pictures of D10 strain of P. falciparum parasites saturated with PQ, washed, and then treated with PQ. Localization of
PQCP in the cytosol is greatly diminished, suggesting that PQ takes up space in the cytosol when interacting with plasmodium
parasites. GFP-Green Fluorescent Protein (ACL-GFP). MTR-Mitotracker Red. PQCP-Primaquine-coumarin probe.
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MERGE
Figure 3.8- Images of Stage IV and V NF54 strain P. falciparum gametocytes treated
with PQCP and MTR. Localization of PQCP in gametocytes is primarily cytosolic.
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CHAPTER 4: IN VIVO ASSESSMENT OF THE MECHANISMS OF ACTION, SYNERGY AND
RESISTANCE OF ANTI-MALARIALS
INTRODUCTION
The emergence of drug resistant malaria parasites hinders eradication efforts by MMV and other
organizations. Therefore, the need for novel therapeutics to combat these resistant parasites has increased
efforts to understand mechanisms of action, resistance, and structure-activity relationships (SAR). Many
old anti-malarials such as primaquine and menoctone have been used to combat malaria infection, but
their modes of action and mechanisms of resistance are not fully understood.
Primaquine (PQ), despite being used for anti-malarial prophylaxis and anti-transmission for over 70
years, has not seen any clinically relevant resistance and treatment failure is rare (84). This phenomenon
is extremely rare for anti-malarials of all classes. Primaquine’s use is limited due to inducing lifethreatening hemolytic anemia in those with glucose 6-phosphate dehydrogenase (G6PD) deficiency.
Despite this limitation, it enjoys synergistic activity when administered with chloroquine (CQ) (102). This
results in clearance of liver and blood stage parasites, resulting in a radical cure. The mechanism of
synergy has been investigated in blood stages, but not in liver stages. Additionally, it is known that CQ
potentiates the liver stage activity of PQ, but whether it is by direct parasite action or by another
mechanism is still unknown (122). Fluorescent probes of PQ and CQ have been synthesized and found to
be effective in localization studies for the erythrocytic stages of Plasmodium (56, 109). Using these
probes, we can determine accumulation of each drug in infected hepatocytes. We hypothesize that
synergism is achieved by differential accumulation of each drug in infected hepatocytes. The differential
accumulation of these parasites could give us information on individual mechanisms in liver stages, as
well as a mechanism of synergy.
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Menoctone is a hydroxynapthoquinone compound, similar to atovaquone. It was assessed as an antimalarial, but studies surrounding it were abandoned due to other more promising leads at the time. Due to
the increase in rates of drug resistance, many older anti-malarials are being investigated to optimize their
effectiveness. Additionally, information about their pharmacology may yield increased understanding
about Plasmodium biology. It has been shown that menoctone is capable of anti-transmission activity due
to its sporozontocidal activity, but its mechanism of action against sporozoites remains to be elucidated
(123).
These studies examine the role of PQ/CQ synergy in liver stages, and in vivo induction of menoctone
resistance in P. berghei parasites. Resistance to menoctone in P. berghei was effectively characterized in
vivo, and was found to confer resistance to atovaquone. The studies surrounding PQ/CQ synergy were
unfortunately inconclusive. Ideas surrounding the reasons for these inconclusive experiments will also be
discussed.
MATERIALS AND METHODS
Mosquito infections, sporozoite production and harvesting
P. berghei ANKA luciferase parasites were obtained from heart puncture from infected BALB/c mice and
injected intraperitoneally into non-infected young female BALB/c mice. Parasitemia was monitored
through tail vein blood smear bi-weekly. Once the parasitemia reached 3-5%, the mice were anesthetized
with a mixture of xylene (10mg/kg), ketamine (100mg/kg), and placed on cartons of 100 3-4 day old,
native female Anopheles stephensi mosquitoes. The mosquitoes were allowed to feed for approximately
30 minutes. After feeding, the mosquitoes were maintained on 10% sucrose inside environmental
chambers at 26°C. On day 21 post-exposure (PE), infected salivary glands were dissected and sporozoites
were isolated and counted. Mice were humanely euthanized following approved IUCAC protocols.
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Animals and Parasites
All mice used in these experiments were female BALB/c mice (the average weight was approximately
18g) obtained from Envigo (Indianapolis, IN). The transgenic P. berghei line 1052 Cl1 (Pb 1052 Cl1)
used in the liver stage assay was obtained from C.J. Janse at Leiden University. This line was generated
from the reference clone of ANKA strain c1115cyl and was designed to express a green fluorescent
protein (GFP) and firefly luciferase. Pb 1052 Cl1 has two copies of the GFP-luc integrated into its
genome. One copy is under the control of a constitutively expressed eef1aα promoter, and the other is
under the control of an ama1 promoter. This study was conducted in compliance with the Guide for the
Care and Use of Laboratory Animals of the National Research Council for the National Academies. The
protocol was approved by the University of South Florida Institutional Animal Care and Use Committee.
Drug screening assay
Hepatocytes were seeded at an optimized density of 17,500 cells per well in a 96-well collagen coated
plate (Becton Dickson, Franklin Lakes, NJ). Sporozoites harvested were added at an optimized 4,000
sporozoites per well (Derbyshire, Prudencio et al. 2012). After 3 hour incubation at 37°C, media was
removed and drugs were added to their respective wells. A 48-hour incubation period yields our end point
where we will lyse the cells with Promega Cell Lysis Reagent Buffer and add Luciferase Assay Reagent.
This catalyzes the firefly luciferase reaction by reacting luciferin with ATP, creating luciferyl adenylate
and PPi. Luciferyl adenylate and oxygen then react to yield oxyluciferin, AMP and light. The amount of
light emitted, which is read by the Perkin Elmer EnVision system, indicates parasite viability. If the
parasite is affected by the drug and is no longer viable, then the luciferase signal will no longer work, thus
determining the viability of the sporozoites after drug treatment. A growth curve was generated from this
data to determine if the compound has liver stage activity.
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Synergy screening of PQ with CQ or QN in P. berghei
To investigate synergy, various drug combinations of PQ with CQ and QN were investigated. We used a
modified protocol from a previous study using 1:1, 3:1, and 1:3 concentration ratios (124). Drug
screening assays were performed as described.
Microscopy of P. berghei infected HepG2 cells with PQCP
In order to evaluate localization of PQCP and the CQ-NBD probe (synthesized in house by the Manetsch
lab) in P. berghei, we used HepG2 cells infected with P. berghei sporozoites as described in Ch. 3, but
using microfluidic devices designed by Dr. Steve Maher at USF (100). After infection, liver stages forms
were allowed to develop for 4 days. 150 M PQCP, 5nM Draq5 stain (Thermo-fisher, Waltham, MA) and
100 M CQ probe were added to P. berghei infected HepG2 cells for 1 hour. Media was removed from
cells, washed with PBS and visualized on the Deltavision microscope using the 10x and 40x objectives.
Generation of menoctone resistance in P. berghei
We used similar methods as used by W. Peters to generate a new menoctone resistant parasite from the
well-characterized P. berghei luc ANKA (125). Infected mice were treated with increasing levels of
menoctone at doses of 3 mg/kg, 30 mg/kg, and 300 mg/kg. Recrudescent parasites were inoculated into
new mice, and subsequent treatment with higher doses of drug led to resistance at a dose of 300 mg/kg.
Resistance was confirmed by the lack of response to subsequent inoculation of high doses of menoctone.
A maintenance dose of 300 mg/kg was used to maintain a high level of parasite resistance.
In vivo antimalarial efficacy against blood stages of P. berghei life cycle (modified Thompson test)
Concisely, five mice were randomly assigned to each dosage group. P. berghei luc ANKA, as well as, Pb
MEN-R were inoculated at 2x106 parasites per mouse. Menoctone was administered orally at 3 mg/kg, 30
mg/kg and 300 mg/kg and atovaquone was administered at 1 mg/kg, 3 mg/kg and 10 mg/kg. Both drugs
were suspended in polyethylene glycol 400 (PEG 400) (Sigma Aldrich, St. Louis, MO) and administered
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via oral gavage at 100 μl per mouse. Dosing by oral gavage occurred once daily for 3 days on days 6 to 8.
Blood films were made on days 3, 5, 6, 9, 12, 15, 18, 21, 24, 27, and 30 post-infection from tail vein
blood to monitor parasite recrudescence.

Elucidation of mutation selection by atovaquone or menoctone
Sensitive and resistant parasites were inoculated into mice and challenged with either atovaquone
or menoctone at different concentrations. Atovaquone was administered to mice at dosages of 1
mg/kg, 3 mg/kg, and 10 mg/kg, and menoctone was given at 3 mg/kg, 30 mg/kg, and 300 mg/kg
respectively. Parasitized blood was then removed and sequenced for cytb mutations.
P. berghei MEN (MRA-414) assessment of atovaquone cross-resistance
Mice were infected with P. berghei MEN and allowed to grow to >4% parasitemia at which
point were challenged with atovaquone at 3 mg/kg, 30 mg/kg and 100 mg/kg. Subsequent
administration of atovaquone at 100 mg/kg was used as confirmation of atovaquone resistance.
RESULTS
Synergy of PQ with CQ and QN. Results of this experiment were inconclusive. Positive and negative
control values were not consistent and varied greatly. In vivo concentrations where PQ has been shown to
be active displayed no activity. Experiment was not repeated due to time constraints and lack of trained
personnel.
Microscopy of P. berghei parasites in HepG2 cells with PQCP. We attempted to determine the
localization of PQCP in HepG2 cells infected with P. berghei parasites in a microfluidic culture model.
These experiments yielded inconclusive results, as characteristic parasite structures could not be located
and analyzed.
Menoctone resistance selection in P. berghei. This study attempted to select for resistance to menoctone
in P. berghei in vivo by using a stepwise selection method. When mice were infected with asexual
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erythrocytic stages and treated with a single dose of menoctone at 3 mg/kg, no decrease in parasitemia
was observed. Blood from these mice was then inoculated into malaria naïve mice and allowed to
develop. After reaching detectable levels of parasitemia, these mice were treated with a single dose of
menoctone at 30 mg/kg. While this treatment resulted in a decrease of parasitemia to less than 1%,
parasites recrudesced to 30% six days later. This procedure was repeated once more, but the dose of
menoctone was increased to 300 mg/kg. Parasitemia was reduced to undetectable levels, but
recrudescence still occurred. This process was once again repeated, taking blood from the recrudescent
mice into malaria naïve mice. In this second passing, recrudescence occurred more rapidly despite
treatment with 300 mg/kg of menoctone. This indicated that parasites were indeed resistant to menoctone
treatment and is notated as MEN-R. Graphical representations of survival groups can be seen in figure 4.1
Assessment of atovaquone cross-resistance in P. berghei MEN resistant parasites. PbMEN-R infected
mice were treated with 3mg/kg ATQ, and saw a decrease in parasitemia to <1%. However, parasites
recrudesced by day 6 post treatment, and reached 10% parasitemia by day 9. Blood was passed into naïve
mice and a dose of 30 mg/kg ATQ was given. Again, parasitemia decreased to <1%, but recrudesced
much faster than the first drug exposure at 4 days post treatment vs 6. The process was repeated, but naïve
mice were treated with 100 mg/kg ATQ. In this group parasites recrudesced by day 7 post treatment.
Successive treatment with 100mg/kg ATQ failed to clear erythrocytic parasites. These trends can be seen
in figure 4.2.
DISCUSSION
The failure to detect PQCP and the CQ-NBD probe was not unanticipated. HepG2 cells are human
hepatic carcinoma cells, which have levels of fluorescently active cytochrome enzymes. Due to the fact
that high concentrations of PQCP are needed for active fluorescence, it is entirely possible that the probe
was unable to be detected in parasites due to the high background of fluorescently active enzymes.
Another possibility is that the infections of the HepG2 cells themselves were unsuccessful. Parasites used
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to investigate localization were not self-reporting due to the nature of the experiment; all available
fluorescent channels were taken up by probes (PQCP, CQ-NBD, MTR). Due to limited time and
materials, other hepatic cell lines were not investigated. If fluorescent detection of liver stage Plasmodium
infection by tagged 8-AQ probes were to be repeated, different cell lines would need to be used or
potentially use another fluorescently active probe to tag the parent 8-AQ molecules.
The synergy studies of PQ with CQ and QN had many potential issues, but two points in the assay in
particular are usually responsible for confounding the experiment. The first of which is sporozoite
viability, which can decrease greatly upon the death of the mosquito during dissection. Decreased
viability would lead to decreased infection rates, which would cause great variability in parasite detection.
This assay in particular requires expression of the luciferase gene in P. berghei luc ANKA to interact with
the luciferase reagent to generate light, which is read by the plate reader. Previous studies in the
optimization of this procedure noted that the luciferase gene would sometimes be knocked out after a
certain number of parasite passages in mice. Therefore, it is also possible that the luciferase gene was
knocked out before the assay even began. Unfortunately, there is no way to assay the activity of this gene
before feeding mice to mosquitos. While there are other ways this experiment could have been
confounded (parasite death, variances in infection rates of cells, etc.), these two reasons represent the
most likely scenarios of experimental failure due to previous studies by the Kyle laboratory.
Menoctone is an older anti-malarial which stopped being investigated due to more promising leads at the
time. These studies were limited in their characterization of menoctone’s anti-malarial properties, leaving
much to be discovered about its anti-malarial mechanisms and pharmacology. This study sought to better
characterize menoctone’s mechanisms via resistance induction. Using a stepwise selection method,
resistance to menoctone in P. berghei parasites was induced. Resistance to menoctone was further
confirmed by cross resistance to atovaquone (ATQ). Using high doses of ATQ, parasites still recrudesced,
even after parasitemia was reduced to less than 1%. This is not unexpected, as ATQ and menoctone are
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both hydroxynapthoquinones; they should exhibit similar anti-malarial activities and potentially similar
mechanisms of action. Indeed, more work surrounding menoctone’s resistance should be investigated.
Menoctone’s effect on parasite mitochondria and elucidation of molecular targets would likely give a
wealth of information about mechanisms of action and resistance.
While the experiments mentioned here are specific to the author’s contributions, a full characterization of
the genotype of resistant parasites, in addition to a more in depth discussion about the ramifications of
this work is included in the full publication by Blake et al under the title “Menoctone resistance in malaria
parasites is conferred by M133I mutations in cytochrome b that are transmissible through mosquitos" in
the journal Antimicrobial Agents and Chemotherapy.
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Figure 4.1- Survival curves of sensitive (A, C) versus menoctone resistant P. berghei (B, D) following treatment with
menoctone or atovaquone. Menoctone offers some protection to Pb luc ANKA infected mice (A), but demonstrates a
marked decrease in protection against menoctone resistant parasites, Pb MEN-R (B). Atovaquone provided significantly
more efficacy than menoctone (C), however even at the highest dose of 10 mg/kg, atovaquone was not effective at
preventing recrudescence of Pb MEN-R (D).
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Figure 4.2- Assessment of ATQ cross-resistance with menoctone in P. berghei MEN (MRA-414). P. berghei MEN infected mice
were treated with 3 (A), 30 (B), and 100 mg/kg (C) on day 0. Confirmations of ATQ cross-resistance with menoctone resistant
parasites was evident by failure to significantly eliminate asexual blood stages parasites with a subsequent does of 100
mg/kg ATQ.
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CHAPTER 5: SUMMARY

Malaria is a disease that affects millions of people, and billions more are at risk of infection. Due to the
increase in resistance to all types of anti-malarial drugs, we need to investigate novel therapeutics, as well
as older potential therapies to combat the spread of resistance. This work seeks to aid those investigations
by exploring the potential of fluorescent probes made with 8-AQ molecules. Using fluorescent tagged
drug molecules is an advantageous way of exploring the drug’s pharmacology and even investigating the
basic science of disease states. This process has been used for cancer medications as well as for antimalarials such as artemisinin and chloroquine. 8-AQ mechanism of action is based upon its metabolites
generated by CYP450 enzymes present in the liver (84, 91, 126). However, how these mechanisms
synergize activity with other anti-malarials such as chloroquine (CQ) is still unknown. By using
fluorescent probes of 8-AQs we hoped to examine co-localization of 8-AQs with CQ fluorescent probes.
We hypothesized that synergism is achieved by differential accumulation of each drug in hepatocytes
infected with Plasmodium.
We created two 8-AQ fluorescent probes, which were characterized by chemical and biological processes.
The synthesis of these compounds proceeds readily. While the yields of these reactions are not excellent,
they are sufficient enough to perform many in vitro and in vivo experiments. Characterization of TQCP
was somewhat hindered by limited research materials; tafenoquine is sold at a maximum size of 50mg.
Synthesizing a batch of TQCP takes the entire bottle of TQ and only gives a 50% yield (25-26mg).
Additionally, TQ is somewhat expensive, so making large amounts of this probe for commercial purposes
will be impractical. Nevertheless, in our hands we saw very similar trends in activity for both probes
when compared the parent molecules. Since PQCP is cheaper to make and easier to characterize than
TQCP, PQCP would be a more attractive choice for commercialization. Additionally, due to the
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aforementioned similarities between PQCP and TQCP, we can suggest that localization of PQCP and
TQCP will be similar in many circumstances.
Unfortunately, localization studies to determine potential mechanisms of synergy were confounded by
reasons mentioned in Ch. 4. While there is evidence for PQ/CQ synergy in vitro and in vivo, the
mechanism of synergy is currently unknown. What was found was that during visualization studies with
PQCP, uptake of the probe only occurred in live samples. Slides with dead P. falciparum parasites fixed
to a slide did not take up PQCP. Therefore, we can suggest that uptake of PQCP (and therefore PQ) is
facilitated by an active transport process. Previous work demonstrated that transport can be investigated
using fluorescent probes of CQ (56). It would be interesting to see if a similar approach could be applied
to infected hepatocytes using fluorescent 8-AQ probes. However, due to confounds in using these probes
in hepatocytes, different probes of 8-AQ should be created to investigate such mechanisms.
To continue this research, it would be especially interesting to tag the molecules with different fluorescent
probes in the red or green absorption range. The EDCI/Dmap coupling reaction can couple any probe
with an active carboxylic acid group to the primary free amine group of 8-AQs. This linkage is especially
effective to preserve activity of 8-AQs, as transformations of the primary amine have been shown to not
significantly impact 8-AQ anti-malarial activity (84). Furthermore, less bulky probes should be
investigated, as trafficking to the mitochondria was not observed in these studies, despite already being
implicated as a potential primaquine target. Another experiment that should be considered is high
resolution mass spectra analysis of these probes after incubation with metabolically active hepatocytes. If
the coumarin moiety is being cleaved due to CYP450 enzyme activity, it would confound experiments by
presenting false positives. If such transformations occurred in vivo, rodent studies would be out of the
question, as coumarin has been shown to be toxic to rodent hepatocytes (127). Finally in 1961, a few
years after primaquine’s initial discovery, P. vivax parasites resistant to PQ were generated in vitro (128).
This work has not seen replication due to the lack of PQ resistance seen in wild type parasites and clinical
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isolates. If this work were to be replicated today, we would be able to determine changes in gene
regulation in the resistant parasites. Additionally, this study includes an example of such a resistance
study via the generation of menoctone resistance in vivo. In order to effectively characterize such gene
regulation, a combination of in vitro and in vivo studies would need to be accomplished.
With our current wealth of information surrounding 8-AQ mechanisms of action, which would include
this study, the question as to why 8-AQ resistance is nearly non-existent would finally be answered.
Answering this question would lead to a new generation of anti-malarial therapeutics based in the 8-AQ
class, and possibly leading to a novel class of anti-malarials. The MMV’s goal of malaria eradication may
not be immediately feasible, but with this work combined with the efforts of others, it is a goal that is not
farfetched.
In the author’s opinion, ROS mediated killing is a mechanism seen in multiple anti-malarial compounds.
This mechanism is a consistent weak spot in Plasmodium, as resistance to ROS generating compounds
such as artemisinin come at a fitness cost to the parasite (75, 129). 8-AQ mediated ROS generation is no
different, as seen by the near non-existent resistance to 8-AQ compounds despite their use for over 70
years. Future anti-malarials, as well as combination therapies, should exploit this weakness in order to
further eradication efforts and reduce incidences of resistance in Plasmodium.
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